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ABSTRACT

THE RELATIONSHIP BETWEEN COBALAMIN DEFICIENCY
AND NEUROLOGICAL DYSFUNCTION

IN OLDER ADULTS

by
Marion Bachra

The prevalence of cobalamin (Obi) deficiency among older adults is

higher than among younger adults, and is estimated to be between 14% and
23%. Persistent Cbl deficiency can cause a variety of neurological deficits.

Neurological dysfunction occurs commonly among older adults, raising the
research question whether or not there is a relationship between the high

prevalence of Cbl deficiency and neurological dysfunction among older adults.
This case-control study enrolled 120 subjects with and without

neurological dysfunction through the Faculty Medical Offices' Internal Medicine
and Neurology Outpatient Clinics. All subjects received a neurological and

cognitive exam. Blood samples were drawn to assess serum Cbl, methylmalonic
acid (MMA), and serum total homocysteine (tHcys) levels. To test the
hypothesis whether Cbl deficient subjects consumed less crystalline (free) Cbl,
Cbl found in fortified foods and supplements, a food frequency questionnaire
was designed.

The prevalence of Cbl deficiency was 16.6% among the "true" controls,
and 25% among the cases(Odds Ratio = 1.7, 95% confidence interval = 0.54 -

5.1). "True" controls had perfect neurological scores, while other control subjects
had reduced vibration sense. Cbl deficiency in older adults was related to low

free Cbl intake, not dietary Cbl intake. Subjects who obtained a daily average of

0 and 1.0 meg of free Cbl were most likely to be Cbl deficient(41.5%), while
those who obtained 2.0 meg of free Cbl were least likely to be Cbl deficient
(13%)(P=.008).

This study was unable to show that older adults with neurological

dysfunction are at greater odds of a Cbl deficiency than a control group. Another
study is needed to determine whether or not older adults with neurological
dysfunction are at greater odds of a Cbl deficiency than a control group without
reduced vibration sense. Furthermore, the relationship between reduced

vibration sense in older and Cbl deficiency needs to be further investigated.

Prophylactic use of Cbl containing supplements among older adults seems

prudent. The current RDA of 2 meg for Cbl needs to be reevaluated in terms of
crystalline Cbl and protein-bound Cbl requirements in older adults.

CHAPTER ONE

I. REVIEW OF THE LITERATURE

A. Rationale for the Study

Cobalamin (Cbl) also called vitamin

has a dual function. First, Cbl is

indirectly involved in cell division ie. hematopoiesis, because of its

interrelationship with folate. Impaired red blood cell synthesis can lead to large
malformed red blood cells or macrocytic anemia. The activity of methionine

synthetase which converts methyl-folate to free folate, and homocysteine to
methionine directly depends on the availability of Cbl. A Cbl deficiency, traps
folate in the methyl form and consequently impairs purine and thymidine

synthesis, and consequently DNA synthesis. Second, Cbl is involved in the
maintenance of myelin surrounding parts of the central and the peripheral

nervous system through an as of yet unidentified biochemical mechanism.
Persistent Cbl deficiency can therefore cause a variety of neurological deficits.
The malfunction of the two known Cbl dependent enzymes methionine
synthetase and methylmalonyl CoA mutase, might be partly responsible for

demyelination of the nerves(Kapedia, 1995). The Cbl dependent methylmalonyl
CoA mutase converts L-methylmalonyl CoA to Succinyl CoA.

Numerous studies report that older people have a higher prevalence of
low serum cobalamin (Cbl) levels than the rest of the population (Yao Y, et al.
1992; Lindenbaum, et al. 1994; Pennypacker, et al. 1992). The clinical

significance of these lower serum values has not been completely sorted out
since lower serum Cbl values are often unaccompanied with elevated mean cell

volumes(MCV)or neurological deficits (Pennypacker, et al. 1992). Neurological

dysfunction occurs commonly among older adults, raising the research question
whether or not there is a relationship between the high prevalence of Cbl

deficiency and neurological dysfunction among older adults. Studies which

compared serum Cbl levels of patients with late onset dementia of the
Alzheimer's type or other types of dementia to patients without such dementias
have given conflicting results (Carmel, et al. 1995; Kristensen, et al. 1993;
Basun, etal. 1994; Crystal, et al.1994). Cbl induced neuropsychiatric deficits
can be complicated by the fact that older people often have multiple medical

problems some of which might interact with tissue Cbl deficiency (Stabler, 1995).
A study is needed to elucidate whether low "normal" serum Cbl values are

part of a normal aging process or if they are more often accompanied, not only
by elevated methylmalonic acid (MMA)and/or total homocysteine (tHcys), but

occur more frequently among patients with detectable neurological deficiencies
or symjDtoms. A reliable way to distinguish between low serum Cbl serum values
which are accompanied with true tissue deficiency and low values which are not,

is to measure serum MMA and serum tHcys levels. The latter two metabolites
can become elevated with Cbl deficiency (Savage, et al. 1994, Lindenbaum, et
el. 1990; Allen, etal. 1990).
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Chapter One will cover the following topics. First, the absorption and
transport of Cbl is discussed to prepare the ground for the different issues
surrounding Cbl malabsorption. Second, the distinction between atypical and

typical Cbl deficiency states is made to explain why the reported prevalence of
Cbl deficiency varies so widely between older and newer studies. Third, the
currently known relationships between Cbl deficiency and neurological signs,
symptoms, and dementia are discussed. Fourth, Cbl deficiency induced
neuropathological changes with its neurological signs and symptoms are
reviewed. Fifth, the rationale for the assessment of dietary protein-bound Cbl

and free Cbl among older adults is supported. Finally, the advantages of using
both serum MMA and serum tHcys levels to detect Cbl deficiency are explained.
The serum levels of these two metabolites may rise during Cbl deficiency.

B. Absorption, and Transport of Cobalamin

Methyl Cbl, 5'-deoxyadenosyl Cbl and hydroxyCbl are the major
biologically active Cbl forms found in animal and fortified foods. In the stomach,
the protein-bound Cbl, only found in animal foods, must be liberated by the
action of hydrochloric acid. The freed Cbl than binds to the salivary R-binder

polypeptides (transcobalamin I, Transcobalamin III, cobalophyllin, hepatocorrin)
(Shevell, 1992). The R-protein Cbl complexes are transported to the duodenum,
where the R-binder protein is split off by the action of pancreatic bicarbonate
and trypsin. The gastric parietal cells produce intrinsic factor (IF) which also
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travels to the duodenum. IF binds to the freed Cbl, and the IF-Cbl complex

travels to the receptors on the ileum, where it is absorbed through calcium

dependent receptor mediated endocytosis into the brush border as shown in
Figure 1 (Festen, 1991; Hunt, 1990).

In the enterocyte, Cbl is released from the IF, and binds to the transporter

protein transcobalamin II (TO II). TOM delivers newly absorbed Cbl in the form of
hydroxy or cyanoobalamin to the major tissues, including bone marrow and
nerve tissue, by receptor mediated endocytosis. Lysosomal digestion releases
Cbl into the cytoplasm as shown in Figure 2. Cbl in the oxidized form is either
converted to reduced methyl cobalamin and used as a coenzyme for methionine

synthetase, or it can enter the mitochondria and be converted to reduced
5'-deoxyadenosyl cobalamin, which is in turn used as a coenzyme for
methylmalonyl CoA mutase as shown in Figure 3(Kapadia, 1995).

C. Pathophysiology of Cobalamin Malabsorption
Protein-bound-Cbl malabsorption due to atrophic gastritis is one possible
etiology for Cbl malabsorption. The prevalence of atrophic gastritis increases
with age. An estimated 40% of people aged 80 or older have atrophic gastritis

(Stabler, 1995). Hypochlorhydria or achlorhydria are the first symptoms of
gastritis which might in turn explain the higher rate of Cbl malabsorption and

lower Cbl levels among older adults. Prolonged gastritis might eventually halt the
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production of IF leading to malabsorption of bound as well as free Cbl (Fasten,
1991). However, van Asselt, et al.(1996) reported conflicting results. Middle

aged people defined as less than 65 years old compared to older people over 65
absorbed free and protein-bound Cbl equally well. Furthermore, protein-bound
Cbl malabsorption was not increased in patients with mild to moderate atrophic
gastritis assessed indirectly by pepsinogen A and C.
Another Cbl malabsorption problem among the elderly might be due to

pancreatic insufficiency, Pancreatic enzyme production also has been shown to
decrease with age (Russell, 1992). However, Schilling (1995) reported that

pancreatic insufficiency rarely results in Cbl deficiency. On the other hand,
diseases of the terminal ileum, such as Crohn's disease are quite often linked to

Cbl deficiency. After Cbl binds to IF, a special ileal receptor is required for
absorption. If the receptor is damaged, malabsorption will occur (Stabler, 1995).
In sum, malabsorption might occur because of the following. First, it might
occur due to the inability to remove the Cbl from the food proteins, because of a

too low hydrochloric acid production. Second, pancreatic insufficiency might lead
to low bicarbonate and trypsin production, making it impossible to digest the
R-protein of the R-protein Cbl complex. Third, Cbl malabsorption can by due to

the halt of gastric parietal cells' IF production or IF destruction by antibodies
resulting in pernicious anemia. Fourth, Cbl malabsorption might be due to the

destruction of the ileum receptor absorption site after ileal disease or surgery.
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The current study allowed the researcher to distinguish between patients
with and without protein-bound Cbl malabsorption, and between patients who
malabsorb both free and protein-bound Cbl. A food frequency questionnaire

was used which specifically focused on protein-bound Cbl and free Cbl intake.
D. Atypical and Typical Cobalamin Deficiency States

The term "atypical" has arisen from the fact that many subjects with Cbl
deficiency do not display the typical macrocytic or megaloblastic red blood cells.
Some subjects only develop neurologic symptoms and never develop
macrocytosis. Many researchers have reported that elderly subjects with

neurological problems and low serum Cbl often show no abnormal hematological
lab values (Healton, 1991; Pennypacker, 1992; Carmel, 1990). Previously, it was
assumed that megaloblastic anemia deveioped prior to the neurological
symptoms, but that notion has been contradicted as early as 1956 when Victor
M. et al. reported several cases with subacute combined degeneration of the
spinal cord who exclusively displayed neurological symptoms and signs.

Atypical Cbl deficiency can be caused by protein-bound Cbl malabsorption,
dietary insufficiency, nitrous oxide anesthesia, and inborn errors of metaboiism
(Carmei, 1990).

On the other hand, typical Cbl deficiency is caused by a lack of intrinsic

factor, and usually displays the classical megaloblastic symptoms with or without
neurological symptoms. However, not all subjects with pernicious anemia display

12

megaloblastic anemia. Therefore, the term "anemia" can be misleading when
anemia is absent among subjects with pernicious anemia (Carmel, 1990).

The current study specifically focused on Cbl deficiency which is atypical
in its expression, namely, neurological and non-hematological, and tried to sort
out how often malabsorption of protein-bound Cbl versus free Cbl occurs.
E. Laboratory Measures to Assess Gobalamin Deficiency

No true gold standard for testing tissue Cbl deficiency exists. Instead, to
get an accurate picture, several laboratory measures should be taken
simultaneously. The most common laboratory measures are: serum Cbl, serum
methylmalonic acid (MMA), and serum total homocysteine (tHcys).
1. Serum Gobalamin as a Measure of Gobalamin Deficiency

The serum Cbl radioactive dilution assay is a laboratory test performed

frequently to assess Cbl deficiency. However, serum Cbl is neither a very

specific nor a very sensitive measure. In general, tissue Cbl stores have only
been moderately correlated with serum Cbl levels, especially in the elderly.
Using a prospective study design, Matchar, et al. (1994) investigated
whether serum Cbl measurements are useful for the diagnosis of Cbl deficiency.

To identify true Cbl deficiency, subjects who had a serum Cbl of less than
180pg/ml and a control group with equal or greater 180 pg/ml of serum Cbl
underwent clinical examination. Subjects were considered deficient when they
excreted less than 7% of radioactive Cbl on the Schillings test, and had a
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hemoglobin of less than 13mg/dl which was responsive to Cbl treatment. They
were also considered deficient if they either had a MCV of greater than 99 fL, a

mean neutrophil lobe count greater than 3.6 per cell, or had macrocytic blood
cells. Subjects were also considered deficient when they had normal Schilling
tests with either a MCV of greater than 99 fl, a mean neutrophil lobe count

greater than 3.6 per cell, or macrocytic blood cells. These diagnostic criteria
were than compared against serum MMA , an objective indicator of tissue Cbl
deficiency. The results were as follows. Only 16 out 72 subjects with low serum
Cbl on the clinical follow up were truly deficient. The positive predictive value of
serum Cbl for diagnosing true Cbl deficiency was only 22%. Eighty-eight
percent of the positives were false positives.

2. Serum Methylmalonic Acid as a Measure of Cobalamin Deficiency

Cbl is the coenzyme needed for the conversion of L-methylmalonyl CoA to
succinyl-CoA. This Cbl dependent metabolic pathway is needed for the
breakdown of branched chain amino acids, threonine, methionine, side chains of

cholesterol, thymine, and odd chain fatty acids as shown in Figure 4. However,
with Cbl deficiency, D-methylmalonyl CoA undergoes hydrolysis to MMA, which
then builds up in the tissues. There is one exception to this build up. A patient
with chronic renal failure will also experience a high serum MMA because of
impaired kidney function (Stabler, 1995).
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The most specific measure to assess Cbl deficiency appears to be serum MMA.
According to Savage, et al.(1994), subjects who have low serum Cbl levels

(<200 pg/ml), but no serum MMA elevation, defined as a level greater than
376 nmol/L or 3 SD above the mean, can be ruled out from being in a deficient
state with a 98.4% certainty.

The following two studies have used elevated serum MMA as a diagnostic

tool to test for Cbl deficiency. Pennypacker, et al. (1992) prospectively screened
elderly without impaired kidney function for Cbl deficiency. Of the elderly, ages
65 to 99, 38 out of 152(25%) had a serum Cbl of less than 300 pg/ml, while of
the controls(17 to 65 years), 10 out of 100(10%) had serum Cbl levels of less
than 300 pg/ml. As shown in Figure 5, serum Cbl levels between the range of
0 and 199 pg/ml were only found among the elderly subjects.
Of the 25 elderly with serum Cbl levels between 201 to 300 pg/ml,

12(48%) had elevated serum MMA(>3 SD), while 7 out 13(53.8%) with serum
Cbl of 200 pg/ml or less had elevated serum MMA. Pennypacker, et al. (1992)
concluded that the conventional "normal" serum level of 200 pg/ml is too low a

reference, since the number of subjects with elevated serum MMA levels were
similar among those with serum Cbl levels between 201 and 300 pg/ml and
among those with 200 pg/ml or less. Figure 6 shows that only one of the

100 controls with a serum Cbl of <300 pg/ml had an elevated serum MMA,
while 19 out of the 38 cases with serum Cbl of <300 pg/ml had elevated serum
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MMA. Lindenbaum , et al. (1994)sought to find out whether the increased

prevalence of low serum Cbl among 548 elderly subjects from the Framingham
Heart study actually reflects tissue deficiency. Figure 7 shows the distribution of
serum Cbl concentrations in 548 elderly subjects and 117 younger control

subjects. Serum Cbl of less than 191 pg/ml was found in 40.5% of the elderly
compared with 17.9% in the controls. Serum MMA were elevated in 15% of
subjects with serum Cbl less than 350 pg/ml, while 10% of the subjects with

serum Cbl greater than 350 pg/ml had elevated serum MMA. Of the 222 elderly
who had a serum Cbl less than 191 pg/ml, 62(27.9%) had elevated serum MMA

concentrations (Lindenbaum, et al. 1994).
Often the elevation of serum MMA precedes the drop of serum Cbl in

patients with established Cbl deficiency. In a previous study by Lindenbaum, et
al.(1990) when Cbl deficient patients due to a gastrectomy or pernicious anemia
received a less than optimal Cbl maintenance therapy for periods of 15 to
66 months, 95% experienced elevated metabolites, but only 69% of them had a
serum Cbl level of less than 200 pg/ml.

Elevated serum MMA levels can vary widely from person to person. This
can partly be explained by the fact that different amounts of propionic acid are

produced by colonic bacteria, and by the use of antibiotics. Lindenbaum, et al.
(1990)found that treatment with lincomycin, an antibiotic which changes the

microbial flora of the gut, resulted in a drastic drop in serum MMA in Cbl
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deficient subject prior to Cbl injection therapy. In conclusion, when those
patients who recently have taken antibiotics, and impaired renal function are
excluded, serum MMA is a very sensitive test, as indicated by the fact that serum
MMA will be elevated 98.4% of the time in patients with clinically proven Cbl

deficiency (Savage, et al. 1994).
3. Serum Total Homocysteine as a Measure of Cobalamin Deficiency

Serum tHcys by itself is a less specific measure than MMA, since it might
either indicate a Cbl, or a folate deficiency. The enzyme methionine synthetase

converts homocysteine to methionine and uses methyl Cbl as a coenzyme. In
this process, the methyl group is transferred from 5'methyl tetrahydrofolate to
methionine. With a folate deficiency, this methyl group is unavailable, and

homocysteine builds up. On the other hand, with a Cbl deficiency, the
methionine synthetase cannot convert homocysteine to methionine, and

homocysteine also builds up. The metabolic interaction between Cbl and folate
are shown in Figure 8.

Both Cbl deficiency and folate deficiency can result in macrocytosis and
megaloblastic anemia. The red blood cells are arrested at an immature state of
development as reflected by an elevated MCV. Large doses of folate
supplementation can mask megaloblastic anemia caused by Cbl deficiency.
However, when Cbl deficiency is wrongfully treated with folate, both serum MMA
and serum tHcys, if elevated, remain elevated. The MCV often drops but
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neurological deficits remain if present. Not until Cbl therapy is initiated do both
metabolites drop (Lindenbaum, et al. 1990).
On the other hand, when folate deficiency is wrongfully treated with Cbl,

serum tHcys remains elevated, and only returns to normal after folate therapy is

initiated (Lindenbaum, et al. 1990). As stated earlier, hematological values used
to confirm serum tHcys accuracy in diagnosing Cbl deficiency are not reliable

since the majority of elderly with low Cbl levels do not have megaloblastic
anemia. Especially, patients with neuropsychiatric disorders often do not display
any hematological abnormalities(Carmel, 1995; Lindenbaum, et al. 1988).
Serum tHcys level is a sensitive measure for Cbl deficiency. According to

Savage, et al. (1994), subjects who have low serum Cbl levels (<200 pg/ml), but
no elevated serum tHcys elevation, can be ruled out from being in a deficient

state with a 95.9% certainty. Their study tested the sensitivity of serum tHcys to
be able to detect Cbl deficiency in 409 Cbl deficient patients. Of the

434 episodes, 416 episodes(95.9%) were accompanied with elevated serum
tHcys, defined as a level greater than 21.3 umol/L or 3 SD above the mean.
The following two studies have used elevated serum tHcys as a

diagnostic tool to test for Cbl deficiency. Pennypacker, et al. (1992)found of the
152 elderly subjects, 25 with serum Cbl between 201 and 300 pg/ml, and
14(56%) had elevated serum tHcys. Eight(62%)of the 13 subjects with serum
Cbl of less 200 pg/ml had elevated serum tHcys. Figure 9 shows the serum
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tHcys levels of the elderly and the controls with a serum Cbl of equal or less
than 300 pg/ml. Of the controls, one out of 10 had elevated tHcys, while 13 out
38 cases had elevated tHcys.

Lindenbaum J, et al.(1994) tested 548 elderly Framingham subjects for
true Cbl deficiency. Serum tHcys was elevated in 39(7.1%) of the subjects.
Serum Cbl was less than 350 pg/ml in 31 (79.5%) of the 39 subjects with tHcys
elevations and was associated with an increased MMA concentrations in

21 subjects. In conclusion, serum tHcys is a very sensitive indicator of tissue
deficient Cbl as indicated by its ability to rule out Cbl deficiency with 95.9%
certainty (Savage DG, et al. 1994).
4. The Advantage of Using Both Serum MMA and Serum Hoys

Savage, et al.(1994)found that 98.4% of iCbl deficient patients had
elevated serum MMA, and 95.0% had elevated serum tHcys. However, when

looking at serum MMA and serum tHcys simultaneously, the sensitivity for
detecting true Cbl deficiency increased to 99.8%.
About 1.4% to 10% of Cbl deficient patients only experience elevated

serum tHcys levels (Stabler, 1995; Allen, et al. 1990). As stated earlier, this is
partly due to variable gut flora between patients and recent antibiotic use. Most
of subjects with folate deficiency will only experience elevated serum tHcys
levels. However, Savage, et al.(1994)found that one out of 119 Cbl deficient

patients experienced both elevated serum MMA and serum tHcys levels.
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F. Prevalence of Cobalamin Deficiency Among Older Adults.
Between the years of 1976 and 1994, the prevalence of Cbl deficiency

among older adults has been estimated to be anywhere from 3% to 32.6%. See
Table 1. The reason for this great variance can be attributed to many different
variables. The most obvious ones are the different biochemical methods and

criteria used to determine Cbl deficiency. Samples have also been taken from

different subsets of the older adult population. But, most importantly, older
studies have used lower serum Cbl cut-off levels, and sometimes as the only

indicator for Cbl deficiency. The more recent studies have used elevated MMA

and tHcys levels, two metabolites which are more sensitive indicators of
biochemical Cbl deficiency. The paragraphs that follow will give an overview of
the different studies listed in Table 1. which have sought to find the prevalence

of Cbl deficiency among older adults.

Elsborg , et al. (1976) was unable to differentiate between folate
deficiency or Cbl deficiency in 78 of the 89 geriatric inpatients with serum Cbl

levels of <200 pg/ml, because of the types of tests done. The prevalence of Cbl
and or folate deficiency was estimated to be 32.6%, The following tests were

performed, formiminoglutamic acid (FIGLU) excretion, MCV, Schilling test I, fecal
fat excretion, D-Xylose test. These tests have many limitations in that they do
not specifically test for Cbl deficiency. Ah impaired urinary FIGLU excretion can
be either the result of a Cbl or folate deficiency. Macrocytosis can either be due
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TABLE 1. PREVALENCE COBALAMIN DEFICIENCY IN OLDER ADULTS

AUTHORS

NUMBER AND
TYPE OF

STUDY
DESIGN

PARAMETERS

USED TO

ESTIMATED
PREVALENCE

DETERMINE

SUBJECTS

COBALAMIN
DEFICIENCY

ElsborgL. et
al. 1976

349 geriatric
inpatients

prospective
pretest posttest
study

Cblof

< 200pg/ml
microbial essay
FIGLU excretion

32.6%folate
or Cbl def.

47 subjects
normal FIGLU

37 subjects
Schilling test,

abn. FIGLU

parti

5 pern. anem.

Cblof

3% Cbl def.

subjects

prospective
study of nutrition
in the elderly

Hanger HO.

204 randomly

cross-sectional

Cbl of

etal.1991

selected free

design

154pg/ml

ifSbl ^
299 pg/ml

2 SO above the

than tested

mean for serum

serum IF,

MMA and thcys

Garry PJ. et
al. 1984

270 healthy
elderly

< 220pg/ml
radioessay
7.3% Cbl def.

living elderly
YaoY.

100 consecutive

cross-sectional

etal.1992

geriatric
outpatients

design

19.7%, based on

parietal cell
antibodies,
serum gastrin,
part 1 Schilling,
MMMHcys
Pennypacker

152 consecutive

cross-sectional

Cbl ^300 pg/ml

LC. et al.
1992

geriatric
outpatients

design

and > 3SD of
MMA and/or

14.5% Cbl def.

thcys
LIndenbaum

548 surviving

prospective

Cbl of <350

J. etal 1994

members of the

observational

pg/ml and

Framingham
study

design

>3SDofMMA

and/or thcys

^12% Cbl def.
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to a Cbl or folate deficiency. The Schilling test I only tests for impaired
crystalline Cbl absorption, not for food-bound Cbl malabsorption. Fat
malabsorption does not necessarily indicate Cbl malabsorption although both
are affected by a decreased production of different pancreatic enzymes.

D-xylose test is used to distinguish diarrhea caused by pancreatic dysfunction
(maldigestion)from diarrhea caused by malabsorption (Pagana, 1992).
Consequently, the use of these less specific tests made it impossible to estimate
the prevalence of Cbl deficiency.

Garry, et al.(1984) used a serum Cbl of less than 220 pg/ml as the cut-off
for Cbl deficiency (20). A radioassay Cbl assay was used which is able to
distinguish Cbl from non-Cbl analogues. Besides the MCV, plasma folate, and

RBC folate, no other parameters were used. The MCV did not correlate with Cbl
deficiency. None of the subjects with serum Cbl levels of less than 220 pg/ml
had macrocytosis. When using a serum Cbl of 220 pg/ml as a cut-off for Cbl

deficiency, only 3% of healthy people aged over 60 were deficient. Subjects with
known medical illnesses were excluded. The authors concluded that Cbl status

among the elderly is not a major medical problem.

Hanger, et al. (1991) used an even lower cut-off level for Cbl deficiency,
namely 154 pg/ml (21). No other biochemical parameters, beside serum Cbl,

were used to check for Cbl deficiency. The authors found the prevalence of Cbl
deficiency among people 65 or older to be 7.3%. The exclusion criteria were
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more stringent than the previous study. Those subjeots living in institutional care
and known to take Cbl supplements, or conditions known to influence Cbl status
were excluded. The use a serum Cbl of 154 pg/ml as the cut-off for Cbl

deficiency might underestimate the prevalence of deficiency among older adults.
The studies to follow all use serum MMA and serum tHcys, two

biochemical markers to test for true Cbl deficiency. Yao, et al. (1992)tested

100 consecutive geriatric outpatients aged 65 or above. Sixteen (16%) patients
had Cbl levels of less than 200 pg/ml. Only 5 patients had their MMA and tHcys
checked, since Medicare refused to pay most of the time. Of those five, four

(80%) had MMA levels greater than 270 nmol/ml (>2 SD), and three(60%) had
tHcys level greater than 16 nmol/ml(>2 SD). Twenty one (21%)had Cbl
between 201 and 299 pg/ml. Of those 21, only nine had their MMA and tHcys
levels checked. Three subject or(33%) had MMA levels greater than
270 nmol/ml, and 11% had tHcys levels greater than 16 nmol/ml. Since so few

subjects had their serum MMA and serum tHcys tested, the authors could only
make rough estimations of the prevalence of Cbl deficiency. Unlike the following
researchers, they used a 2 SD above the mean as the cut-off for elevated MMA

and Hoys. Based on this cut-off, the estimated prevalence of Cbl deficiency
among older adults was 19.7% (Yao, et al. 1992).

Pennypacker, et al. (1992)screened 152 consecutive geriatric
outpatients. Cbl deficiency was defined as a Cbl level of equal or less than

29

300 pg/ml with elevated MMA and/or tHcys levels of 3 SD above the mean.
Using these criteria for deficiency, they found that the prevalence of Cbl

deficiency was 14.5%. Fifty-six percent of the subjects with Cbl ranging from 201
to 300 pg/ml had elevated MMA and/or tHcys levels, compared to 62% for
subjects with Cbl levels of less than 200 pg/ml.

Lindenbaum, et el.(1994) decided that a 350 pg/ml Cbl level should be

the cut-off for suspecting a possible Cbl deficiency based on the fact that
elevated serum MMA and serum tHcys levels occurred in 18% of the subjects
with serum Cbl levels of between 300 and 349 pg/ml (14). They looked at the

548 surviving members of the Framingham Heart study, and found that 222

(40.5%) had a Cbl of less than 350 pg/ml. Of those 222, 11.3% and 5.7% had
elevated MMA and tHcys level, respectively. They found the prevalence of Cbl
deficiency to be 12% or greater in healthy older adults.

G. Comparing Neurological Signs in Older Adults at Different Cobalamin
Levels

The Framingham study found that 40.5% of the healthy elderly subjects
had serum Cbl levels below 350 pg/ml. Of those elderly subjects, 27.9% also
had elevated MMA >376 nmol/L), a truthful indicator Cbl deficiency, when those

with impaired renal function are excluded. This study found a true Cbl deficiency
of 12% or greater among older adults, however these subjects were not

systematically tested for neurological deficits (Lindenbaum , et al. 1994)
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In the study of Metz, et al. (1996), the cases did not score significantly
differently on the neurological test and the Mini Mental State Exam than the
controls. However, that might partly be due to the fact that some of the controls
were actually cases since 19% of them had elevated tHcys without concurrent
folate deficiencies. Even though, the mean tHcys levels in the cases were

significantly higher than in the controls, 25.0 nmol/ml versus 15.5 nmol/ml

(P 0.008), 40% of the controls had elevated tHcys levels, compared to 76% of
the cases. No separate neurological testing was done to compare the scores of
those with true Cbl deficiency to the scores of those without Cbl deficiency.

Healton, et al. (1991) also found no correlation between the severity or

presence of neurological impairment and low serum Cbl level. But, they tested
only those subjects with Cbl deficiency. Consequently, these insignificant results
can be due to a restriction of the Cbl range used, and the fact that serum Cbl
level is an insensitive test for Cbl deficiency. They did not specifically compare

serum MMA and serum tHcys levels against neurological impairment.

Pennypacker, et al. (1992) did find that those with elevated MMA and
tHcys levels had a higher degree of neurological impairment than those without
such elevations. A neurological score of zero indicated that the patient was

neurologically completely normal. After Cbl treatment, the mean neurological
impairment score dropped in the Cbl deficient outpatients, and two groups
scored neurologically similarly.
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Hanger, et al. 1991 looked specifically at the mental and cognitive status
of older adults with low serum Cbl, defined as 154 pg/ml, and those with normal

serum levels(>154 pg/ml). They found no correlation between mental status,

cognitive status, and serum Cbl levels. As pointed out previously, older adults

can experience Cbl deficiency at a wide serum range, and therefore serum Cbl
is too insensitive a test.

From the previous studies, it can be concluded that the question of

whether there is a higher prevalence of Cbl deficiency among older adults with
clinically diagnosed neurological deficits than among older adults without such
deficits has not yet been fully answered. The current case-control study does not

stratify patients by serum Cbl levels which is very unreliable, but stratifies the
patients by clinically diagnosed neurological deficits using a standard

neurological exam (Healton, et al.1990; Metz, et al.1996).
H. Are Dementia Patients More Likely to be Cobalamin Deficient?
The Cobalaminerglc hypothesis proposes that Cbl deficiency might be

etiologically important in a sub-group of patients with Alzheimer's disease(AD)
(McCaddon A, 1992). Others propose that a low serum Cbl is a marker for AD,
that cognitive decline will continue in spite of normalization of serum Cbl levels
after treatment. A correlation of 0.38 at P< 0.05 was obtained for cognitive

decline as measured by the Mini Mental State Exam (MMSE)and serum Cbl
values in patients with AD type dementia (Levitt, et al. 1992). On the other hand.
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the fourth edition of the Diagnostic Manual of Mental Disorders(DSM-IV) wants
the physician to use serum Cbl as a differential diagnosis. Dementia due to

other general medical conditions ie. Cbl deficiency has its own special ICD-9
code. The DSM-IV excludes the possibility of an interaction between dementia
of all types and a Cbl deficiency.

Unfortunately, the current data is not so clear-cut as the DMS-IV
proposes. There are many conflicting study results regarding the relationship
between Cbl deficiency and AD type dementia as well as other types of

dementias. Lower Cbl levels have been reported in patients diagnosed with AD

type dementia compared to patients with other types of dementias or controls

(Carmel, et al. 1995; Kristensen, et al. 1993). While others report that serum Cbl
levels are not more often reduced in patients with AD type dementia (Basun, et

al. 1994; Crystal, et. 1994). These conflicting results are partly due to different
research criteria, different assays, different serum Cbl cut-offs, and whether or

not serum MMA and serum tHcys were used to determine if the low Cbl levels
existed concomitantly with a frank Cbl deficiency. The following paragraph will
take a look at some of the currently existing conflicting research results.

Crystal, et al. (1994) performed a prospective study on elderly aged 75 to
85. After a five year follow up, they found no correlation between those who had

dementia as defined by neuropsychological tests (the Blessed test of

Infdrmation, Memory, and Concentration and the Fuld Object Memory Evaluation
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tests) and low serum Cbl values as defined by less than 150 pg/ml. However,

this study used low serum Cbl as the only marker for Cbl deficiency. It lacked
some vital laboratory assessments, since true Cbl deficiency cannot be
determined by serum Cbl values alone. In order to distinguish between a true

positive and a false positive, serum MMA and tHcys have to be measured.
Basun, et al.(1994) conducted a cross-sectional survey and compared
serum Cbl levels of patients with AD type dementia, vascular dementia, other

dementias, and non-demented patients. No significant difference in mean serum
Cbl level was found in any of the four groups. An age effect for serum Cbl levels

was only observed in the non-demented patients. Older non-demented patients
had significantly lower serum Cbl values than their counterparts. Age specific
prevalence rates of Cbl deficiency, defined as 200 pg/ml, for non-demented, AD
type dementia, other dementias were 15.5%, 18.1%, and 14.4% respectively,
and did not differ in a statistically significant way. Again, serum MMA and serum

tHcys were not analyzed to assess whether the low Cbl levels corresponded with
a true Cbl deficiency.
Kristensen, et al.(1993)found that older patients with AD dementia more

often displayed true Cbl deficiency than older patients with other dementias,
mental disorders, and the controls. Twenty seven percent of the AD patients
either displayed subnormal Cbl levels and/or elevated serum MMA, while only
8% of the patients with other dementias, 4% of the patients with mental
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disorders, and 5% of the controls had subnormal Cbl levels and/or elevated
serum MMA.

From the previous studies it can be concluded that more studies are
needed to determine whether or not older dementia patients are more prone to

Cbl deficiency than non-demented controls. Only Kristensen, et al (1993)
assessed the serum MMA and tHcys levels. The current study attempted to
assess whether or not the prevalence of Cbl deficiency is higher among

demented outpatients Dementia was defined by a MMSE score of 24 or less in
conjunction with a history and physical which met the DSM-IV diagnostic criteria,
than a comparable non-demented control group. Cognitively impaired patients,
was numerically defined by MMSE score of 25 or 26, in conjunction with a

history and physical which met the DSM-IV diagnostic criteria for amnestic
syndrome (Levitt, et al. 1992).

I. Cobalamin Deficiency induced Neuropathoiogic Changes
In 1900, the term subacute combined degeneration of the spinal cord was

coined. This syndrome expresses itself neurologically, hematologically, and
cellularly as epithelial atrophy of the tongue lining (Rowland, 1995). While

neurological symptoms and signs are always present, the hematological and
cellular signs are sometimes absent as reported by Shevell in 1956. In addition
to neurological signs and symptoms, Cbl deficiency can also cause psychiatric
problems such as agitation, irritability, memory loss, psychosis, hallucinations.
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and dementia. Others have also reported that Cbl Induced neurological

problems often occur in the absence of abnormal hematological findings, and
that they might even be inversely related (Lindenbaum, et al. 1988; Healten, et

al. 1991). Lindenbaum, et al.(1988)found that 40 of 141 (28%) patients with Cbl
deficiency had no anemia or macrocytosis. As stated earlier, the type of Cbl
deficiency which strictly presents itself neurologically has been called atypical
Cbl deficiency, because of its atypical non-hematological presentation.
Cbl deficiency can cause a symmetric loss of myelin in the posterior-

lateral columns, lateral corticospinal tracts, and spinalthalmic tracts of the spinal
cord, the peripheral nerves, the cerebral cortex and cranial nerves (Victor, 1956;
Allen, et al. (1995). The demyelination of the spinal cord initially affects the

cervical and upper thoracic axonal tracts (Savage, 1995), then proceeds in any

direction across the spinal cord (Rowland LP, 1995). When the lateral
corticospinal tracts become affected, it can cause, hyper or hypo platelar
reflexes or lead to absent reflexes, clonus, and babinski. Spinalthalmic tract
involvement can cause decreased cutaneous sensation. Posterior column tract

involvement can lead to decreased or absent vibration sense, a positive

Romberg, and decreased joint position sensation (Victor, 1956). Compared to

spinal cord involvement, diffuse lesions of the peripheral sensory or
sensorimotor nerves can lead to a similar neurological clinical presentation. A

clinical neurological examination is not able to differentiate between a the spinal
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cord and/or peripheral nerves involvement(Savage, et al.1995). Both, the large

myelinated fibers and the small unmyelinated fibers can become damaged,
reducing position and vibratory sense, pain and temperature perception,
respectively (Rowland, 1995).
Currently, it is thought that the demyelination is either induced by the
impaired actions of two Cbl dependent enzymes, namely, methionine synthetase

or methylmalonyl CoA mutase. The first hypothesis was supported by the fact

that methionine supplementation with induced Cbl deficient animals would
postpone the onset of Cbl induced neuropathy (Metz, 1992). It is believed that
the unavailability of methyl groups due to decreased synthesis of S-adenosyl
methionine leads to impaired myelin synthesis. Myelin is predominantly made up
of cholesterol, glycolipids, phospholipids, and myelin basic protein. Methyl

groups are needed for the synthesis of phospholipids and myelin basic protein
(Kapadia, 1995). The other hypothesis states that Cbl induced impairment of
methylmalonyl CoA mutase results in the accumulation of MMA and propionyl
CoA which is thought to replace malonyl CoA and acetyl CoA as substrates in
fatty acid synthesis leading to the formation and incorporation of unusual fatty

acids into myelin (Kapadia, 1995).
J. Neurological Symptoms and Signs of Cobalamin Deficiency

The following paragraphs give an overview of the neurological symptoms
and signs in Cbl deficient patients (Healton, et al. 1991). The most common
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initial symptom was bilateral paresthesias. a painful burning and tingling
sensation that can affect the feet or both the hands and feet. Ataxia without

paresthesias can also be an initial symptom, although ataxia usually occurs at a
later stage, and in combination with paresthesias.
Diminished or absent vibratory sensation in the feet or feet and legs up to
the knees was the most common neurological finding. The second most

common finding was diminished or absent proprioception in the toes and ankles.
Sometimes the fingers and wrists were also affected. Cbl induced mental

impairment such as global dementia, memory loss with a mildly reduced
attention span, depression, agitation, paranoid psychosis, and personality
changes was the third common finding. Diminished or absent cutaneous pain
sensations was the fourth common finding. Sensations were most commonly
diminished or absent in the feet or feet and legs up to the knees. However,

sometimes the arms, wrist, forearms, or biceps were also involved. Weakness of
the limbs as witnessed by hyper or hyporeflexia, and absent or weak tendon
reflex was the fifth most common finding. A positive Romberg was the sixth most

common finding. Autonomic abnormalities due to Cbl deficiency such as urinary
and fecal incontinence, postural hypotension were not seen very often, as was
Cbl induced visual impairments.

Healton, et al. (1992)found an inverse relationship between neurological
impairment and hematocrit. The duration of neurological symptoms was
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positively correlated with neurological impairment. On the average, subjects
without neurological impairment had lower MCVs than subjects with neurological
impairment. There was no correlation found between the severity or presence of
neurological impairment and the serum Cbl level. All the subjects responded to
Cbl treatment, of which 47% experienced a complete recovery. The severity of
neurological impairment as well as the duration of the symptoms were strong

determinants of whether or not there was complete recovery.
K. Dietary Cobalamin Intake Among Older Adults

Many studies on Cbl deficiency among the older adults have been done.
However, only a few selected studies have attempted to assess dietary

adequacy. Most Americans eat a large variety of animal products and fortified
cereals, and it is, therefore, assumed by most researchers that older adults get
more than enough dietary Cbl in terms of the Recommended Daily Allowance

(RDA)of 2 meg. The following paragraphs will evaluate this assumption by
evaluating some of the dietary assessments that have been done to estimate Cbl
intake.

A national study of 474 participants revealed that 15.4% of the men and
17.3% of the women above the age of 74 obtained below two-thirds of the RDA

for Cbl through dietary means. Between the age of 65 and 74, 8.7 of the men
and 19.7 of the women obtained below two-thirds of the RDA. However, of those

consuming below two-third of the RDA, 36% of the men, and 40% of the women
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reported taking a vitamin and/or mineral supplement. No further assessment of
the supplements were performed (Ryan, et al. 1992).

Blundell. et al (1985) hypothesized that Cbl deficiency among elderly

hospital inpatients is often due to a nutritional deficiency since their subjects'
serum Cbl levels rose after admission to the hospital. However, this study did

not systematically evaluate the patients' average dietary Cbl intake. Elsborg, et

al.(1976) also found that when elderly patients were placed on a hospital diet
that the serum Cbl levels rose.

Garry, et al. (1984) did do a dietary Cbl analysis, and found that the
median Cbl intake was close to 3 meg a day for the older subjects . Forty-two

percent of the men had intakes below the RDA, while 10% had an intakes of less
than 50% of the RDA. While, 65% of the women in this study had intakes below

the RDA, and 15% had intakes of less than 50% of the RDA. Note that the RDA
in 1984 was set at 3 meg, and not at the current RDA of 2 meg.

Carmel, et al. (1995) attempted to assess dietary histories of dementia
patients, but they had too many logistical problems administering the food
frequency questionnaire, and 24 hour recall. Consequently, their results on the
adequacy of dietary Cbl were inconclusive.

Considering the previous studies, it is not quite clear whether or not most
older adults get sufficient dietary Cbl through their diet, especially free or

crystalline Cbl Free Cbl is found only in fortified foods and supplements. In light
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of the fact that food-bound Cbl malabsorption (Cbl in animal foods) might be

quite common among older adults, no researcher seem to have systematically
studied free and protein-bound Cbl intake among older adults. This current study

specifically assessed free and protein-bound Cbl intake. Dietary needs of Cbl
for older adults might be higher than the current RDA of 2 meg, because of the

different absorptive problems older adults can encounter with aging (Russell,

1992). Oral supplementation or food fortification with free Cbl might be needed
for this older population (Russell, 1997). Furthermore, the current 1989 RDA
does not distinguish between crystalline and protein-bound Cbl (National
Research Counsel, 1989).

CHAPTER TWO

II. OUTLINE OF THE RESEARCH PROJECT

A. Summary of Rationale for the Research Project

The prevalence of cobalamin (Cbl) deficiency among older adults is

higher than among younger adults, and is estimated to be between 14% and
23%. Persistent Cbl deficiency can cause a variety of neurological deficits.

Neurological dysfunction occurs commonly among older adults, raising the
research question whether or not there is a relationship between the high

prevalence of Cbl deficiency and neurological dysfunction among older adults.
Permanent neurological damage can occur if Cbl deficiency is mistaken for other
diseases such as Alzheimer's dementia, multiple sclerosis, diabetic neuropathy,

or amyotrophic lateral sclerosis (Schilling, 1995).
A study is needed to elucidate whether low "normal" serum Cbl values are

part of a normal aging process or if they are more often accompanied, not only
by elevated methylmalonic acid(MMA)and/or total homocysteine (tHcys), but
occur more frequently among patients with detectable neurological/cognitive
deficiencies or symptoms.

B. Main Study Objective and Hypotheses
1. Main Study Objective

Our primary objective is to determine whether older adults(60 years or
older) with a diagnosed neurological and/or cognitive dysfunction (cases) have a
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higher prevalence of Gbl deficiency than a comparable group without such
neurological and/or cognitive deficits (controls).
2. Hypotheses

1. The proportion (prevalence) of controls with true Cbl deficiency as defined by
a serum Cbl of <400 pg/ml and a MMA of >271 nmol/L and/or a serum Hoys of
>13.9 umol/L (estimated to be 18%)will be lower than for the cases (estimated
to be 38%).

2. The odds of having Cobalamin (Cbl) deficiency is estimated to be 3.75
higher for subjects with neurological and/or cognitive dysfunction (cases)
compared to the odds of the control subjects .

3. Older adults with neurological and/or cognitive dysfunction consume less free
Cbl (from fortified foods and supplements)than the control subjects.

4. Subjects who consume a higher amount of free Cbl are less likely to be Cbl
deficient.

0. The Study Design, Setting, and Sampie Size Caicuiation
1. Study Design

A case control study which used 120 outpatients 60 years or older with
and without neurological and/or cognitive deficits was conducted.

2. Setting
Subjects were recruited through the Loma Linda University Faculty
Medical Offices, an outpatient clinic. Control patients were strictly recruited
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through the Department of General Internal Medicine and were seen by Dr.
James Larson, the principal investigator, and Marion Bachra, a graduate
nutrition student and author. Cases were recruited both through the Department

of General Internal Medicine and the Department of Neurology and were seen

by various internists, neurologists, including Dr. Daniel Giang, a co-investigator,
and author.

3. Sample Size Calculation

The prevalence of Cbl deficiency in healthy free-living older adults is
estimated to be around 18% (Lindenbaum, et al. 1994, Pennypacker, et al.

1990). To be able to detect an odds ratio of 3.75 or greater, at a power level of
80%, at an alpha level of 0.05, 60 cases and 60 controls were needed for this

study. Epi Info Version 6.0 was used to do the power calculation. See Appendix
1 for the power calculations for the odds ratios 5 through 1.5.

D. Subjects, Exclusion Criteria and Sequence of Data Collection
1. Subjects

Thirty female and 30 male controls, 27 female and 33 male cases ages 60

through 107 were enrolled when the exclusion criteria listed below were met.
Exclusion Criteria

1. Patients with neurological demyelinating diseases, movement disorders,
seizure and epilepsy syndromes, neuropathies, neuromuscular disease due to
specific pathological conditions were excluded.
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2. Patients with asymmetricar presentation of neuroldgical signs or symptoms
were excluded.

3. Suspected diabetics, defined as a fasting blood sugar above 140 gm/dl, or a
random blood sugar above 200 mg/dl and diagnosed diabetic were excluded.
4. Patients with previously diagnosed pernicious anemia were excluded.
5. Patients with previously diagnosed Cbl deficiency ie. pernicious anemia were
excluded.

6. Patients who orally took more than 25 meg of Cbl per day, or who had
previously received Cbl injection therapy were excluded.

7. Patients previously diagnosed or suspected with spinal stenosis, spinal
compression, and all rediculopathy related to specific structural problems were
excluded.

8. Patients receiving chemo or radiation therapy, or those who experienced
peripheral neuropathy after treatment were excluded.
9. Patients with untreated or partly treated hypothyroidism were excluded.
10. Patients with multiple myeloma and those who tested positive for
monoclonalgammopathy were excluded.

11. Patients with diagnosed or suspected strokes, multi-infarcts, peripheral
vascular disease, cerebral hemorrhage, and brain tumors were excluded.

12. Patients with a creatinine level above 2.0 mg/dl were excluded.
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2. Sequence of Data Collection Events for Cases
1. Outpatients visited either Dr. Larsen, Dr. Giang or other FMO doctors for

neurological and/or cognitive complaints. Some patients were enrolled without
neurological symptoms, but were tested neurologically by the MD to have a

neurological deficit. To speed up the data collection process, the Clinical Lab
saved serum of all patients who had their serum Cbl levels tested. The author

would approach the doctor who ordered the test to see if the patient met the
study criteria, and to get approval to invite the patient to enroll in the study.
2. Patient was asked to participate in the study, read and sign the informed
consent form. Appendix 2 shows the two separate consent form for the cases
and the controls.

3. During the first visit, the physician administered the neurological exam and the
Mini Mental State Examination (MMSE)(See Appendix 3).
a. The author administered the MMSE with all the cases who strictly

enrolled because of a neurological deficit. The author administered the

Trail Making Test, Part B with all the cases and all the controls. Scores
were filled out on the neurological score sheet and check list
(AppendixS).

b. The physician ordered a Complete Blood Count, a Chemistry Blood
profile, Serological testing for syphilis (only for cognitive impairment).
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protein electrophoresis, a thyroid panel, and serum Cbl on a special
SmithKline Beecham lab slip with a label indicating that two vials with
1.5 ml each serum should be frozen.

0. Two vials, each with 1.5 ml of serum were frozen and saved for
Metabolite Laboratories, Inc. in Denver,

d. The author administered and filled out the Food frequency
Questionnaire.(Appendix 4)

a. The author checked the patients' medical records and filled out a
Patient Profile Sheet(Appendix 3)

4. After all the data had been collected, aliquots of those patients with a serum

Cbl of equal or less than 400 pg/ml were sent to Metabolite Laboratories in
Denver where serum MMA/tHcys were analyzed.

3. Sequence of Data Collection Events for Controls
1. Patients visited Dr. Larsen for a medical condition other than a neurological or
cognitive complaints.

2. Patients were asked to participate in the study, read and sign the informed
consent form (Appendix 2)

3. During the patients' regular visit. Dr. Larsen administered the neurological
testing (Appendix 3)
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a. The author administered the MMSE and Trail Making Test. All the

scores were filled out on the neurological score sheet and Check list
(Appendix 3).
b. Dr. Larsen ordered serum Gbl on a separate and special research

SmithKline Beecham lab slip with the Grant Billing Address. CBC and
Chem Profile were only ordered when medically indicated.
c. Two vials, each with 1.5 ml of serum were frozen and saved for

possible transport to Metabolite Laboratories, Inc. in Denver.
d. Marion administered and filled out the Food frequency questionnaire
(Appendix 4)
8. The author filled out a Patient Profile Sheet(Appendix 3)

4. After all the data had been collected, aliquots of those patients with a serum
Gbl less than 400pg/ml were sent to Metabolite Laboratories in Denver where
serum MMA/tHcys were analyzed.
E. Biochemical Assessment of Blood Samples

The following laboratory values were documented on the patient profile
sheet. Serum Gobalamin, serum total homocysteine, serum methylmalonic acid,
mean cell volume, hemoglobin, hematocrit, blood urea nitrogen, creatine, total
cholesterol, albumin. (Appendix 3)
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F. Neurological Impairment Measurements and Scores
The higher the neurological score the greater the neurological impairment

(Healton et al, 1991; Metz et al. 1996). Maximum total points were 23 points on
the neurologic testing scale (Appendix 3).

A neurological deficit was defined as a neurological score of 4 or above,
excluding those who had reduced vibration sense and/or hyporeflexia in the
absence of paresthesias. Absence of neurological deficit was defined as a
score of 4 or less in the absence of paresthesias. Patients with peripheral

neuropathy/myelopathy with and without paresthesias were enrolled. Those who
experienced gait imbalance in the absence of paresthesias or peripheral
neuropathy/myelopathy were also enrolled. Patients who had paresthesias in the
absence of other neurological signs were also enrolled.

G. Cognitive Impairment measurements and scores
1. Mini Mental Status Examination (Tombaugh, 1992)

Maximum score is 30 points. The MMSE is divided in the following 6 categories;
1. Five points for orientation to time
2. Five points for orientation to place

3. Three points for registration of three words

4. Five points for attention & calculation
5. Three points for recall of three words

6. Nine points for language & visual construction
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Criterias for Cognitive impairemeht:

27-30= no cognitive impairment

25-26= mild cognitive impairment, and based on a history & physical
assessment (Levitt, et al 1992)

24-5= moderate to severe cognitive impairment(dementia of uncertain etiology,
and based on a history and physical).
2. Trail Making test Part B

The Trail Making Test part B, a test of visuomotor tracking, attention, as

well as cognitive impairment, was not used as a diagnostic tool since this test
has not yet been standardized to account for the very pronounced age effect.

(Kennedy, 1981). This test requires the subject to continuously scan the test
page to identify and draw a continuous line between letters and numbers in
alphabetical and numerical order. Results are reported In seconds, number of
errors of omissions and commissions.

H. Dietary Assessment

A short semi-quantitative dietary questionnaire was developed by Dr.
Sabate and the author to assess protein-bound Cbl as well as free Cbl intake.
This questionnaire is divided into six sections, namely, 1. vitamin

supplementation, 2. eggs and dairy products, 3. meat, poultry and fish products,
4. Cbl fortified meat substitutes/meat analogues, 5. bread and Cbl fortified cereal
products, and 6. Cbl fortified liquid food supplements. When the subjects
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reported supplement use, they were ealled at a later time to report the name
brand, the exact amount of free Cbl per tablet(s), and were asked how often, and
for how long they had taken the supplement. During their doctor's visit, the

subjects were asked how often they ate a specific serving size of food, either per
day, per week, per month. If they consumed a particular food less than once a
month, consumption was assumed too be rarely or never, and the number zero
was written in the "rarely/none" column (Appendix 4).

Nutritionist IV diet analysis, version 4.1. was used to Compare dietary Cbl
against the RDA of 2 meg. For statistical analysis, the values of the cumulative
Cbl intake (dietary and supplemental intake), and free Cbl intake (free Cbl from
diet and supplements) were used.
I. Statistical Methods

Data were entered and analyzed using SPSS 7.0 for Windows. The
following variables had strongly right skewed and/or leptokurtic distributions;
age, education, MCV, MMA, Crt, BUN, dietary Cbl intake, free Cbr intake,

supplementary Cbl intake, total Cbl intake, MMSE score, neurological score, and
Trails B test score and were log-transformed. Parametric statistics were

performed with normally distributed variables. If the log transformations did not
result in a normally distributed variable, non-parametric statistics were
calculated. For most of data analysis, the subjects were either stratified

51

according to whether they were cases or controls, or whether they had a Cbl
deficiency or not.

To compare the subjects, the independent f-tests were done for the

following variables Cbl, log-MMA, tHcys, log-age, log-MCV, Hgb, Hot, log-Crt,
log-BUN, and log-total Cbl intake. The Mann-Whitney was used for the MMSE
score, years of education, free Cbl intake, and supplemental Cbl intake. The

Mann-Whitney test was also used to test whether mean rank of free Cbl intake
differed among lacto-ovovegetarians and omnivorous. The independent f-test

was done specifically to compare controls with a neurological score of zero and
controls with decreased vibration sense in terms of the mean log-serum Cbl, the
mean log-serum MMA, and the mean serum tHcys.

The two-variable Chi-square test was performed to compare the

frequency counts of females and males, omnivores and lacto-ovovegetarians,
and among the cases and the controls, and among those subjects who were Cbl
deficient or not. The two-variable Chi-square test was done to assess frequency

of supplement use, dietary Cbl, free Cbl, among controls and cases by age, and
among Cbl deficient and not deficient subjects.
The odds ratio was obtained to assess whether the cases were at greater

odds of having a Cbl deficiency. The prevalence of Cbl deficiency was estimated
to be 18% for the controls (Lindenbaum, et al. 1993, Pennypacker, et al. 1992)
and 38% for the cases. The latter percentage was based on the sample size
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calculation. The odds ratio was diso calculated for the controls with a

neurological score of zero and controls with decreased vibration. Several odds
ratios were calculated to assess specifically whether controls with a neurological
score of zero were a greater odd of having a Cbl deficiency the cases, or those
cases with specific isolated neurological deficits and/or diagnosis.

The bivariate association between variables was tested by calculating the
Pearson or Spearman coefficients of correlation. To investigate the effect of the

group factor (case or control) a multivariate analysis of factors predicting the
following normally distributed variables; serum Cbl, log-serum MMA, serum
tHcys, log-neurological score, and the log-Trials B test, the stepwise multiple
linear regression model was used to select the most strongly related normally

predictor variables, and to calculate a multiple unadjusted R^.
One-way ANOVA was performed to compare serum Cbl, free Cbl intake,
log-serum MMA, and the log-serum tHcys means among the different

neurological diagnoses. One-way ANOVA with the Bonferroni multiple
comparisons procedures was performed to compare the mean log-ages of cases
and controls who had normal, reduced or absent platellar reflexes, and normal,
reduced or absent vibratory sensation.
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A. ABSTRACT

Objectives: To determine whether older adults with neurological dysfunction are
at greater risk of cobalamin deficiency than subjects without neurological

dysfunction, and whether those with cobalamin deficiency have a lower intake of
free cobalamin.

Design: Case-control study in which clinical and laboratory assessments of
consecutive outpatients were surveyed.

Setting: Outpatient clinic at Loma Linda University, California.

Participants: One-hundred and twenty older outpatients aged 60 to 107.
Measurements: Neurological examination. Mini Mental State Examination, Trail
Making Test - Part B, dietary Questionnaire, serum determinations of cobalamin,
methylmalonic acid, total homocysteine, and folate.
Resuits: The prevalence of cobalamin deficiency was 16.6% for those controls

with completely normal neurological exams, and 25% for the cases (0R=1.7,
95% Cl .54, 5.1). Inclusion of controls with reduced vibration sense resulted in
an odds ratio of 1.2(95% Cl .52, 2.8). Cbl deficiency was associated with a
lack of low free cobalamin, cobalamin obtained from fortified foods and

supplements. Subjects who obtained a daily average between 0 and 1 meg of
free cobalamin were most likely to be cobalamin deficient (41.5%), while those

who obtained ^2 meg were least likely to be cobalamin deficient(13%)(P=.003).
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Conclusions: Subjects with neurological dysfunction trended towards a higher
odds of cobalamin deficiency when compared to controls with completely normal

neurological exams ("true controls), but, because of the consequent decrease in
sample size, this trend failed to reach statistical significance. Isolated reduction
of vibration sense may not exclusively be a manifestation of normal aging, but it

may also be an early neurological sign of cobalamin deficiency. Incorporation of
free Cbl in the diet, in the form of supplements or fortified foods, may reduce the
risk of cobalamin deficiency in older adults.
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B. INTRODUCTION

Persistent cobalamin (Cbl) deficiency can cause a variety of neurological
deficits including: myelopathy, peripheral neuropathy, and cognitive impairment
(1-7). Many studies report that older adults have a higher prevalence of low
serum Cbl levels as well as Cbl deficiency than the rest of the population. The
estimated prevalence of Cbl deficiency among older adults is somewhere
between the range of 12 to 23% depending on what cut-offs are used as serum

methylmalonic acid(MMA)and serum total homocysteine (tUcys) normals
(8-11). Myelopathy, peripheral neuropathy and cognitive impairment are

prevalent in older adults (4), raising the possibility that Cbl deficiency may be a
risk factor for these deficits. To our knowledge, no study has systematically

investigated whether older people with neurological signs and/or symptoms of
unknown etiology have a higher prevalence of Cbl deficiency than a comparable
control group. The Cobalaminergic hypothesis proposes that Cbl deficiency
might be etiologically important in a sub-group of patients with Alzheimer's

disease (AD), others propose that low serum Cbl is a marker for AD (12,13).
Attempts to confirm these relationships have yielded conflicting results (14-21).
Only a few selected studies have attempted to assess the dietary

adequacy of Cbl intake in older adults (22-24). None of these studies assessed
free Cbl intake. Free Cbl is found in both fortified foods and supplements, while

protein-bound Cbl is found exclusively in animal products. Most Americans eat a
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large variety of animal products and fortified cereals, and it is therefore for
generally assumed that older adults get more than enough dietary Cbl in terms
of the recommended daily allowance(RDA)of 2 meg (24,25). However, a

national study of 474 participants revealed that 15.4% of the men and 17.3% of
the women above the age of 74 obtained below two-thirds of the RDA for Cbl

through dietary means, excluding supplements. Between the age of 65 and 74,
8.7% of the men and 19.7% of the women obtained below two-thirds of the RDA

for Cbl, excluding supplements. Of those consuming below two-third of the
RDA, 36% of the men, and 40% of the women reported taking a vitamin and/or
mineral supplement (26).

Dietary needs of Cbl for older adults might be higher than the current

RDA of 2 meg, because of absorptive problems older adults may encounter with
aging (27). Furthermore, the current 1989 RDA doesn't distinguish between free
and protein-bound Cbl needs (28). Older adults might need oral a supplement
or consume foods fortified with Cbl (29). Protein-bound Cbl malabsorption might

be quite common among older adults (30,31). However, a recent study failed to
confirm that older adults more often malabsorb protein-bound Cbl than middle

aged adults (32). The current study addresses this contradiction, by assessing
whether Cbl deficient subjects consumed less free Cbl. Specifically, free Cbl
}

(Cbl from fortified foods and supplements) as well as dietary Cbl (protein-bound
Cbl and free Cbl from fortified foods) are analyzed.
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In sum, the present case-control study examined, first of all^whether
subjects with neurological and/or cognitive dysfunction are at greater odds of
having Gbl deficiency. Second of all, whether Cbl deficiency occurred more
often among those subjects who consume less free Cbl.
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C. METHOD

1. Outpatients

One-hundred and twenty patients, aged 60 or older, who visited the

Faculty Medical Offices in Loma Linda California between March and October of
1997 were enrolled consecutively in a case-control study. Sixty controls were

exclusively obtained from the Department of Internal medicine, while 60 cases
were obtained from Internal Medicine, the Alzheimer's clinic, and the Department

of Neurology. Cases were enrolled when diagnosed with a neurological and/or
cognitive deficit as outlined below. This project was approved by the Institutional
Review Board of Loma Linda University Medical Center.
2. Exclusion Criteria

The following types of subjects were excluded. Subjects with diagnosed
demyelinating diseases, movement disorders, seizure disorders, neuropathies of
known etiology, and neuromuscular diseases. Subjects with unilateral
presentation of neurological signs or symptoms. Subjects with known spinal
stenosis, spinal compression, and all radiculopathies related to specific

structural problems. Subjects receiving chemo or radiation therapy. Subjects with
partially treated hypothyroidism. Subjects with multiple myeloma and those who

tested positive for monoclonal gammopathy. Subjects with suspected multiinfarcts, previous cerebral vascular accidents, and previous cerebral

hemorrhage. Subjects with impaired renal function defined by a creatinine level
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above 2.0 mg/dl. Suspected diabetics, defined as a fasting blood sugar above

140 gm/dl or a random blood sugar above 200 mg/dl, and diagnosed diabetics.
Recently diagnosed Cbl deficient subjects, and those diagnosed with pernicious
anemia. Subjects who orally took more than 25 meg of Cbl per day, or who had
recently received Cbl injection therapy.

3. Diagnostic criteria for neurological deficit
Subjects were enrolled as cases when they experienced neurological
symptoms or exhibited neurological signs. A neurological scoring system, as

previously described by Metz et al. (1997) was used to conduct the neurological
testing (33). As a general rule, subjects with a neurological score of 4 or greater
were considered to have a neurological deficit, with the exception of those who

displayed reduced vibration sense and hyporeflexia as their sole deficit (34).
Cases were enrolled with the following diagnosed neurological symptoms and/or
signs. Paresthesias in the absence of peripheral neuropathy reported by the
patient as a sensation of numbness, burning or tingling. Peripheral neuropathy

which was defined as one of the following minimum combinations of neurological
deficits with and without paresthesias: reduced vibration and one or more errors

in joint position sense; absent vibration sense and absent reflexes; and absent
reflexes with or without a positive Romberg. It should be noted that a clinical

examination is unable to distinguish between a peripheral neuropathy and a

myelopathy, because of similar neurological signs (5). In the presence of
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paresthesias, the following minimum combinations of neurological deficit were
also classified as peripheral neuropathy: absent vibration sense with reduced
reflexes ; reduced vibration sense with absent reflexes; reduced vibration sense;
and reduced cutaneous sensation. Patients with gait imbalance without any

other neurological signs or symptoms were also enrolled in the study.
4. Diagnostic criteria for cognitive deficits
First time outpatients (cases) were either enrolled through the Alzheimer's

clinic or through the Neurology Department. Patients received a complete work
up which consisted of a history and physical examination, and

neuropsychological examinations: a geriatric depression scale, activity of daily
living assessment, a Mini Mental State Examination, Trail Making Test, Part B,
and a neurological exam. The cases were either categorized as having mild
cognitive impairment, or dementia of uncertain etiology with or without peripheral

neuropathy. Suspected vascular dementia was ruled out based on the history
and physical, and CT scan when available. The patient was diagnosed with

dementia of uncertain etiology when the DSM-IV diagnostic dementia criteria
were met, and when the MMSE score was 24 points or less (13,35). The patient
was diagnosed with mild cognitive impairment when the DSM-IV diagnostic
criteria for amnestic syndrome were met, and when the MMSE score was 25 or
26 (13,35).
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5. Diagnostic criteria for the controls
A comparable control group was enrolled through the Internal Medicine
Clinic who experienced no neurological or cognitive deficits or symptoms.
6. Nutritional assessment of Cbl intake

To assess Cbl intake, a food frequency questionnaire was developed
which differentiated between protein-bound Cbl and free Cbl containing foods.

Nutritionist IV diet analysis, version 4.1. was used to estimate dietary Cbl intake
from Cbl containing foods. Total Cbl intake was defined as dietary and

supplemental Cbl intake, free Cbl intake as Cbl from fortified foods and
supplements, and supplemental Cbl as Cbl from supplements. Care givers
supplied the dietary information of the cognitively impaired cases.
7. Laboratory Methods

The Bio Rad Quantaphase II

Radioassay was used to assess the

patients Cbl level. In this assay the serum is combined with a solution containing
dihiothreitol, labeled Cbl, and cyanide. All the various forms of Cbl bound to the
binding proteins are converted to cyanocobalamin. Intrinsic factor is added, and

the mixture is incubated during which the endogenous and labeled Cbl compete
for the binding sites based on their respective concentrations. The supernatant

with unbound Cbl is discarded while the Cbl concentration is determined by
counting the pellet's reactivity and by using Bio Rad's standard curves (Bio-Rad

Diagnostics group). Serum MMA and serum tHcys were measured using
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capillary gas chromatography-mas$ spectrometry as previously described in
detail (36,37).
8. Definitions of Cobaiamin Deficiency

Cbl deficiency was defined as a serum Cbl level of <400 pg/ml, and a
serum methylmalonic acid (MMA)of >271 nmol/L(>2 SD above the reference

mean)(38), or in conjunction with serum total homocystein (tHcys) of >13.9
umol/L (>2 SD above the reference mean). Cbl deficiency was also defined as a
serum tHcys of >13.9 umol/L, in conjunction with a folate level >5 ng/ml (9,30).
The 400 pg/ml cut-off was chosen because 97.4% of the Framingham elderly
population with elevated serum MMA levels(>3 SD)had serum Cbl levels <400
pg/ml, while 2.6% with elevated serum MMA levels(>3 SD)had serum Cbl levels
between 400 and 700 pg/ml (8).

Serum folate levels were checked when patients had elevated serum
tHcys levels to determine whether the elevation was due to a Cbl and/or a folate
deficiency. A serum tHcys level of >13.9 umol/L without elevated serum MMA

levels, in conjunction with a folate level <5 ng/ml was considered to be primarily
a folate deficiency with a possible Cbl deficiency.
9. Statistical Methods

Data were entered and analyzed using SPSS 7.0 for Windows. The
following variables had strongly right skewed and/or leptokurtic distributions;
age, education, MCV, MMA, Crt, BUN, dietary Cbl intake, free Cbl intake.
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supplementary Cbl intake, total Cbl intake, MMSE score, neurological score, and
Trails B test score and were log-transformed. Independent f-tests. One Way
and Two Way ANOVA, Pearson correlations, and multiple linear regressions

were performed with normally distributed variables. If the log transformations did
not result in a normally distributed variable, Mann-Whitney, Kruksal-Wallis, one

and Two Variable Chi-square, Bionomial test, odds ratios, and Spearman
correlations were performed. For most data analysis, the subjects were either
stratified according to whether they were cases or controls, or whether they had
a Cbl deficiency or not. Statistical significance was set at P <.050.
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□.RESULTS

Outpatients
The 60 cases included 33 women and 27 men aged 60-107 with a mean

(±SD) age of 77 ± 8.2. The 60 controls included 30 women and 30 men aged 6597 with a mean (±SD) age of 77 ± 6.7. Neither their mean ages nor female to
male ratio differed significantly (P=.225; P=.583). The mean years of education
was 13.7 years for the controls and 13.1 years for the cases (P=.172) (Table 1).
Biochemical and Hematological Findings among the Cases and the
Controls

The cases and the controls were very similar in terms of serum Cbl, Blood

Urea Nitrogen (BUN), creatinine (Crt), mean cell volume (MCV), hematocrit
(Hot), and hemoglobin (Hgb) levels (Table 1). Figure 1. shows the distribution of
serum Cbl concentrations among the cases and the controls. One case who was
also Cbl deficient, and none of the controls had a serum Cbl level below 100

pg/ml. Seven cases, three of which were Cbl deficient, and two controls who
were also Cbl deficient, had serum Cbl levels between 100 and 200 pg/ml.
Fourteen controls, seven of which were Cbl deficient, and ten cases, six of which

were Cbl deficient, had serum Cbl levels between 201 and 300 pg/ml. Thirteen
cases, four of which were Cbl deficient, and 11 controls, four of which were Cbl

deficient, had serum Cbl levels between 301 and 400 pg/ml. None of the cases
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had serum levels above a 1000 pg/ml, while two of the controls did. The weak
correlation between age and serum Cbl did not reach significance
(R= 17, P=.068).

Biochemical and Hematoiogical Findings among Subjects with and without
Eievated Metabolites

Table 2. compares the biochemical and hematoiogical findings of subjects
with serum Cbl of <400 pg/ml, with and without elevated metabolites. Subjects
with elevated serum tHcys levels were significantly older and included more

females than subjects without such elevation (P=.002; P=.004). The mean BUN
was higher for the subjects with elevated serum tHcys levels (P=.001). Subjects
with elevated serum MMA levels had lower serum Cbl levels than subjects
without elevated serum MMA levels (P=.021).

Frequencies of Eievated serum MMA and serum tHcys among Cases and
Controls

Table 3. shows the frequencies of elevated serum MMA, serum tHcys
levels, and Cbl deficiencies among the cases and controls. Thirteen controls had
elevated serum MMA , and a Cbl deficiency. Five controls had elevated serum

tHcys levels, four of which had a Cbl deficiency. Four controls had an elevation
of both metabolites, while nine controls had only elevated serum MMA levels.

One control had just an elevated serum tHcys level with serum folate of less than
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5 ng/ml, and was assumed to have a folate deficiency with a possible Cbl
deficiency.

Fifteen cases had elevated serum MMA, and a Cbl deficiency. Seven

cases had elevated serum tHcys levels, of which four had a Cbl deficiency. Four
cases had an elevation of both metabolites, while 11 cases had only elevated
serum MMA. Three cases had only elevated serum tHcys levels with serum

folate levels of less than 5 ng/ml, and were assumed to have a folate deficiency
with a possible Cbl deficiency.
The prevalence of Cbl deficiency was 13 out of 60(21.7%) for the

controls, and 15 out of 60(25%)for the cases. When looking at the cases by
diagnosis, the prevalence of Cbl deficiency was 3 out of 13(23%)for cases with

peripheral neuropathy without paresthesias, 5 out of 17(29.4%)for cases with

peripheral neuropathy with paresthesias, 2 out of 6(33%)for cases with
paresthesias only, 1 out of 4(25%)for cases with gait imbalance, 1 out 4(25%)
for cases with mild cognitive impairment, and 3 out of 16(18.8%)for cases with
dementia of unknown etiology (P=.666).
Cognitive and Neuroiogicai Findings
Mini Mental State Examination Scores

The mean (± SD) MMSE score was 25 ± 7 for the cases and 29 ± 1 for the

controls (P=.001)(Table 1). Cases diagnosed with mild cognitive impairment
and dementia of unknown the etiology, had mean MMSE scores of 25 ± 1 and
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15 ± 7, respectively. The variables age and MMSE score were not significantly
correlated (R=-.11; P= 0.253). The mean rank MMSE score did not differ among
the different serum Cbl categories (P=.378). There was no correlation between
serum Cbl and the MMSE scores(R= -.12; P=.205). MMSE scores were

positively correlated with years of education for the all the subjects (R=.37,
P=.001), for the cases and the controls separately (R=.34, P=.001; R=.40,
P=.001).
Trails B Test Scores

The mean (± SD)Trails B test score of 153 ± 60 sec. for the cases was
significantly higher than the mean Trails B test score of 128 ± 60 sec. for the
controls (P=.016)(Table 1). But, the mean errors of omission and commission
were no different for the cases compared to the controls (P=.496; P=.758).

Cases with mild cognitive impairment(n=4) had a mean (±SD)Trails B test score
of 175 ±88 sec. Only 3 of the 16 dementia patients were able to complete the
Trails B test, and their mean (± SD)score was 220 ± 83 sec.
The variables age and the Trails B test scores were positively correlated
for all the subjects(R=.28, P=.005), for the controls (R=.28, P=0.034), but not for
the cases (R=.25, P=.098). For the cases, the Trails B test scores were a
function of mental status, since the MMSE scores and the Trails B Test scores

were inversely correlated (R=-.40, P=.007). Education and the Trails B Test

scores were inversely correlated for all the subjects only (R=-.32, P=.001).
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Neurological Scores
The mean (±SD) neurological score of6 ± 4.2 for the cases was

significantly higher than the mean score of 1 ± 1.4 of the controls (P<.001)
(Table 1). But, those who were Cbl deficient did not score higher on the
neurological test than those who were not Cbl deficient(P=.305)(Table 2).
Twenty-eight of the 60 controls had a reduced vibration sense, and eight
controls hypo platellar reflexia. Absent vibration sense, absent platellar reflexes,
joint position errors, and positive Rombergs were the most commonly seen
neurological signs among cases diagnosed with peripheral neuropathy without
paresthesias.

Age was the only variable significantly correlated with the neurological
scores. For all the subjects, the correlation was(R=.34, P<.001), for the controls
it was(R=.40, P=.001), and for the cases it was(R=.32, P=.013). Neither serum

Cbl, serum tHcys, nor serum MMA were significantly correlated with the
neurological scores (R=-.10, P=.294: R=.10, P=.456: R=:.12, P=.383).
For the cases, impaired reflexes and impaired vibration sense were
positively correlated with age (R=.35, P<.001; R=.42, P<.001). For the controls,

reduced vibration sense was positively correlated with age (R=.33, P=.009).
Furthermore, cases with normal vibration and with reduced vibration sense had

younger mean ages of 74.6 yr and 77.9 yr, than those cases with absent

vibration sense with 85.3 yr. (P=.002; P=.012). Also, cases with normal platellar
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reflexes had a younger mean age of 76 yr than those with absent platellar
reflexes who had a mean age of 84.5 yr (P=.009). Of the controls, those with
normal and reduced platellar reflexes had mean ages that did not differ

significantly, 76 yr versus 79 yr. (P=.063). But, controls with normal vibration
sense had a younger mean age of 74.9 yr than those with reduced vibration
sense who had a mean age of 79.3 yr (P=.009).

Table 4. compares the odds ratios of Cbl deficiency for cases to the

controls subjects and to "true" control subjects. A "true" control had a
neurological score of zero. Even though, none of the results reached statistical
significance, due to the small sample sizes, there was a definite trend of
increasing odds ratios when comparing "true" controls to controls, and "true"
controls to the cases. First, when the controls were compared against the

cases, the odds ratio was 1.2 (.52, 2.8). Second, when only those controls with
reduced vibration sense were compared to the cases, the odds ratio was 1.0

(.35, 2.8). Third, when controls with reduced vibration sense were compared
against the "true" controls, the odds ratio was 1.7 (.46, 6.0). Fourth, when the
"true" controls were compared to the cases, the odds ratio was 1.7 (.54, 5.1).
Fifth, when the "true" controls were compared to the cases and controls with
reduced vibration sense the odds ratio was also 1.7 (.59, 5.1). Because of this

trend of increasing odds ratios, odds ratios were calculated for "true" controls
and only those cases with either specific neurological diagnoses or deficits who
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appeared to have a higher prevalence of Cbl deficiency (not statistically
significant) than all the cases combined (Table 5).
Dietary findings

Two cases, one with and one without Cbl deficiency and three controls,

one with and two without Cbl deficiency, had a dietary Cbl intake <2/3 of the

RDA. However, only that one case with Cbl deficiency and none of the controls
had a total Cbl intake (dietary and supplemental Cbl) <2/3 of the RDA. Twentysix of the cases(43%), and 36 the controls(60%)reported using a daily

supplement with Cbl (P=.068). On the other hand, 8 out of 28(29%)subjects
with a Cbl deficiency reported taking a daily supplement with Cbl, compared to

54 out of 92(59%)subjects without Cbl deficiency (P=.005). The most frequently
used Cbl dosages were either 6 meg, 9 meg or 25 meg. Being older, over
74 years of age, compared to being younger, between 60 and 74 years of age,
did not effect whether a case or a control consumed either less dietary Cbl, free
Cbl or supplemental Cbl (P=.737; P=.975; P=.786).
Fifty of the cases and 50 of the controls were omnivores, while 10 of the
controls and 10 of the cases were lacto-ovovegetarian. Of the 20 vegetarians,
five had a serum Cbl levels <400 pg/ml, and three out of 20(15%) had a Cbl

deficiency. Of the 100 omnivores, 53 had a serum Cbl level <400 pg/ml, and 25
out 100(25%)were Cbl deficient (P=.583). Omnivores had a lower mean free
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Cbl intake of 5.5 ±7.1 meg, than lacto-ovovegetarians who had a mean intake of
9.9 ± 9.8 meg (P=.009).

The mean (± SD)dietary Cbl intake was 4.8 ± 2.35 meg for the eases, and
was higher than the dietary Cbl intake of the eontrols who had an mean intake of
3.9 ± 2.0 (P=.046). However, the mean free Cbl intake was signifieantly higher
for the eontrols, namely, 7.7 ±8.1 meg , versus 4.7 ±7.1 meg for the eases

(P=.004 ), while the mean total Cbl intake did not differ, 10.7 ± 8.1 versus 9.6 ±
7.5 meg (P=.473)(Table 1). Subjeets with Cbl defieieney were more likely to
eonsume less free Cbl (3.1 ± 6.4 meg)than those without Cbl defieieney (5.4 ±
7.4, P=.032). Twelve subjeets with elevated serum tHeys, of whieh all but four

were also Cbl defieient, were more likely to eonsume less free Cbl as well as
less total Cbl than subjeets without elevated serum tHeys levels (2.9 ±8.1; 4.7 ±

6.7, P=.041)(7.5 ± 10.5 ; 10.4 ± 7.5, P=.001)(Table 2.)
For the purpose of analyzing the relationship between free Cbl intake and
Cbl defieieney, free Cbl intake was divided into the following three eategories; 0
to 1 meg, 1.1 to 1.9 meg, and 2.0 meg and up. Seventeen out of 41 (41.5%) were
Cbl defieient in 0 to 1 meg eategory. Two out of 10(20%)were Cbl defieient in
the 1.1 to 1.9 meg eategory, and nine out of 69(13%)were Cbl defieient in the

2.0 meg and up eategory (P=.003). Of the 28 Cbl defieient subjeets, 17(61%)
subjeets obtained between 0 and 1.5 meg of free Cbl , while 11 (39%)subjeets
obtained between 2 and 29 meg of free Cbl (P=.571).
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There was a positive correlation between serum Cbl and total Cbl intake,
and serum Cbl and free Cbl intake for all the subjects (R=.23, P=.013: R=.28,

P=.002), as well as for the controls(R=.38, P=.002: R=.41, P=.001). Total and
free Cbl intake were also inversely correlated with serum tHcys for all the

subjects (R=-.39, P=.003: R=-.42,P=.001), as well as for the controls (R=-.46,
P=.015: R=-.44, P=.021), while just free Cbl intake was inversely correlated with
serum tHcys for the cases {R=-.40, P=.025). Finally, free Cbl intake was

inversely correlated with serum MMAfor all the subjects (R=-.26, P=.047), but
not for the cases and controls separately (R=-.86, P=.116; R=-.23, P=.251).

Table 6. displays the Pearson or the Spearman correlation coefficients among
the significantly related variables for the cases and controls separately, and
combined. Of the three Cbl intake variables, only free Cbl intake is shown, since
free Cbl intake correlated with more variables the other two.

Multiple-linear Regression Findings
Serum Cobalamin Predictors

Using stepwise multiple linear regression, free Cbl intake predicted 18%
of the variation in the controls' serum Cbl levels (P=.002), while serum tHcys and
serum MMA predicted 23% and 16% of the variation in the cases' serum Cbl
levels (P=.042; P=.014). None of the other variables significantly contributed the
linear regression models.
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Serum Total Homocysteine Predictors

The variables age and free Cbl intake predicted 50% of the variation in
the controls' serum tHcys levels (P=.001), while variables age and total Cbl

intake predicted 32% of the variation in the serum tHcys levels for all the
subjects (P=.001). BUN and serum Cbl predicted 37% of the variation in the
cases' serum tHcys levels (P=.009). None of the other variables significantly
contributed to the linear regression models.
Serum Methylmalonic Acid Predictors

The variable serum tHcys predicted 24%, 25%,.and 22% of the variation
in serum MMA levels for all the subjects, as well as for the cases and the

controls separately (P<.001, P=.004, P=.013). None of the other variables
significantly contributed to the linear regression models.

Neurologlcal Test Score Predictors

The variables age and the Trials B test score predicted 23% of the
variation in the neurological score for all the subjects (P=.008). Age predicted

16% of the variation in the neurological score for the controls (P=.001), and 10%
of the variation for the cases (P=.004). None of the other variables significantly
contributed to the linear regression models.
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Trails B Test Score Predictors

The variable age and education predicted 21% of the variation in the

Trails B test scores for all the subjects (P=.001), while the variable age predicted
7% of the variation the controls' Trails B test scores (P=.001). Sixteen percent of
the cases' variation of the Trails B test scores were explained by the MMSE

scores (P=.007). None of the other variables significantly contributed to the
linear regression models.
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E. DISCUSSION

The prevalence of Cobalamin deficiency was 16.6% for those controls
with completely normal neurological exams, and 25% for the cases(0R=1.7,
95% 01 .54, 5.1). Inclusion of controls with reduced vibration sense resulted in
a prevalence of 21.7%(0R=1.2, 95% 01 .52, 2.8). Though widely accepted as
"normal" aging, inclusion of subjects with isolated reduced vibration sense may
have contaminated the control group. Twenty eight of the 60 controls had
reduced vibration sense. Healton, et al.(1991) reported reduced vibration sense
to be the most common neurological sign among Obi deficient patients (2). It was
not clear whether this symptom ever occurred as an initial sign of Obi deficiency.
Reduced vibration sense, in the absence of other signs or symptoms, usually

has been considered "normal" for older adults (34,39). In our study, controls
with reduced vibration sense appeared to be at increased odds of being Obi
deficient than "true" controls (0R=1.7; 0.46, 6.0). Future studies are needed to
determine, whether older adults with reduced vibration sense are at greater

odds of Obi deficiency than a control group without reduced vibration sense.
In the current study, Obi deficient subjects did not demonstrate a higher

level of neurological impairment than Obi non-deficient subjects. Pennypacker,
et al. (1992) did find that subjects with Obi deficiency demonstrated a higher

level of neurological impairment than Obi non-deficient subjects (11), while Metz,
et al. (1996)found no neurological difference among the cases and the controls
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(33). However, the latter study stratified the cases and controls based on serum
Cbl level, and consequently, eight of the 43 controls had definite Cbl
deficiencies. No separate statistical analysis was done to compare the

neurological scores of those without and with a true Cbl deficiency.
In our study, age and the Trails B Test score were the only variables
which correlated with the neurological score. For older adults, age might be a

better predictor of the severity of neurological dysfunction than biochemical Cbl
deficiency, since in our study, a severe neurological dysfunction in the oldest

subjects often occurred in the absence of a biochemical Cbl deficiency. On the
other hand, biochemical Cbl deficiency quite often occurred in the absence of

neurological dysfunction. The retrospective nature of this study was a major
limitation, and therefore the latter observation could not be further explored, in
that asymptomatic Cbl deficient subjects at the time of the study could have
developed neurological signs or symptoms in the future.
The correlation between the Trails B Test and the neurological score

might indicate that some subjects with neurological dysfunction have slowed
visuomotor tracking abilities (40). However, for the cases, the Trails B test score
was a function of mental status, not the Trails B score. MMSE scores and the
Trails B Test scores were inversely correlated, while age was not significantly
correlated with the Trails B Test scores. Like previous studies, education and
the Trails B Test scores were inversely correlated for all the subjects (41), while
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age and the Trails B Test scores were positively correlated (41,42). The mean
Trails 8 test score of the controls was higher than the mean score previously

reported of a similar age group (43), while the mean score was comparable to a
study in which no differentiation was made between normal cognition and of
impaired cognition (41).

Unlike, previous studies, the correlation between serum Cbl and age did
not reach significance (8,32), nor with the MMSE scores (13). But, like previous
studies, serum Cbl did correlate with supplemental Cbl intake (8,22), but even

more strongly with free Cbl intake (free Cbl form fortified foods and Cbl
supplements).

This study also examined the relationship between Cbl deficiency, and

free Cbl intake among older adults. Previous researchers have usually assumed
that dietary Cbl intake gives little insight to the subjects' Cbl status (25), which
our study confirmed. However, in terms of free Cbl intake, subjects who
obtained between 0 and 1 meg of daily free Cbl were more likely to be Cbl

deficient than those subjects who obtained ^2 meg,(41.5% versus 13%). When
looking at Cbl supplementation, 20 of 28(71%) Cbl deficient subjects reported to
not take Cbl supplements, compared to 41% of the non-deficient subjects. A

previous study reported that 86% of Cbl deficient subjects, and 69% of the nondeficient subjects reported to not take Cbl supplements (8). In our study, Cbl
deficiency in older adults is more associated with a lack of free Cbl, than with
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dietary Cbl intake. Only one of the 120 subjects obtained <2/3 of RDA for total
Cbl. Incorporation of free Cbl in the diet, the form of supplements of fortified
foods, may reduce cobalamin deficiency in older adults.
Savage et al. 1995 and Healton et al. 1994 reported to have never
observed Cbl deficiency induced cognitive impairment in the absence of other

neurological deficits (2,5). However, only two of the four cognitively impaired and
Cbl deficient subjects had neurological impairment, while one of the cognitively
impaired with neurological impairment did not have a Cbl deficiency. The

prevalence of elevated metabolites appeared to be lower among the cognitively
impaired than among cases with other neurological diagnoses as well as the
controls. Joosten, et al. (1997) did observe that subjects with Alzheimer type

dementia have higher elevated metabolite levels than a control group (21).
In conclusion, more studies are needed to confirm the trends found in this

study that older adults with isolated reduced vibration sense are at greater odds
of a Cbl deficiency than a comparable control group with completely normal

neurological exam. A future study should also determine whether older adults
with specific neurological deficits/diagnosis are at greater odds of Cbl deficiency
than a control group with a normal neurological exam. Cbl deficiency in older
adults is more associated with a lack of free Cbl, than with dietary Cbl intake.

Incorporation of free Cbl in the diet, the form of supplements of fortified foods,
may reduce cobalamin deficiency in older adults.
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Figure 1. Distribution of Serum Cobalamin Levels among 60 cases with neurological Dysfunction and 60 Controls
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.410"

.001

.204"

.041"

.187

.713

.566

.163

.081

.001

NA

NA

.335

.002

.004§

P-vaiue

(2-tailed)

Subjects with Cbl<400pg/ml N=58

.058

.200"

.032"

.057

.590

.545

.753

.076

.265

NA

NA

.021

.083

.300

P-value

(2-tailed)

Subjects with Cbl<400 pg/ml N=58

Table 2, Characteristics for Cases and Controls Combined with & without Elevated Metabolites

00
CO

4(5)

Neuro score

3(3)

148(71)

.305

.170

4(3)

144(84)

3(4)

135(57)

.325

.847

f Mann-WhItney test

1:80 = standard deviation
§ Chl-square test

tTo convert Cbl values to pmol/L, divide by 1.355.

supplements, MSSE = Mini Mental State Examination.

volume. Hot = hematocrit, Hgb = hemoglobin Diet Cbl = dietary Cbl Intake only. Free Cbl = free Cbl obtained from fortified food and
supplements, Suppi Cbl = free Cbl obtained from supplements only. Total Cbl = free and protein-bound Cbl obtained from food and

*Cbl = cobalamin, MMA = methylmalonic acid, tHcys = total hotnocysteine, BUN = blood urea nitrogen, Crt = creatinine, MCV = mean ceii

123(47)

Trails B(sec)

Table 2.(Continued)

00
CD

elevated

(>13.9 umol/L)

7 (11.7)

5 (8.3)

4(6.7)

4 (6.7)

No. (%)

& tHcys

No. (%)

Both MMA

tHcys

11 (18.3)

9 (15)

No. (%)

MMA only

>2SD

3(5)

1 (1.7)

No. (%)

tHcys only

> 2SD

45(75)

47(78.3)

No. (%)

metabolites
Elevated

Neither
Definite

15(25)11

13 (21.7)11

No. (%)

Deficiency

Cbi*

Possible

3(5)

1 (1.7)

No. (%)

Deficiency

CbP

§ Possible Cbl deficiency Is defined as a tHcys level >13.9 umol/L with a serum MMA level < 272 nmol/L and a serum folate level of < 5ng/L
II Odds Ratio = 1.21 (95% confidence Interval = .52, 2.8)

tHcys level >13.9 umol/L and a serum folate ^ 5 ng/ml.

t Definite cobalamin (Cbl) deficiency Is defined as a MMA level >271 nmol/L or a MMA level >271 nmol/L & a tHcys level > 13.9 umol/L or a

* Normal range for serum methylmalonic acid (MMA)Is ±2 SD or 73-271 nmol/L
t Normal range for serum total homocysteine (tHcys) is ±2 SD or 5.1-13.9 umol/L

15 (25%)

Cases n=60

13(21.7%)

Controls n=60

No. (%)

> 2 SD MMA*
(>271 nmol/L)

>2SD+

Table 3. Frequencies of Elevated Serum Methylmalonic acid and Serum Total Homocysteine among Cases and

Controls

CD

o

60

28
30

30
30

Controls

Controls with Reduced Vibration

"True"* Controls

"True"* Controls

"True"* Controls
reduced vibration

Cases & controls with

Cases

Vibration sense

Controls with reduced

Cases

Cases

CASES

"True control" are defined as controls with a neurological score of zero ^

n

CONTROLS

88

60

28

60

60

n

1.7

1.7

1.7

1.0

1.2

Ratio

Odds

(.59,5.1)

(.54,5.1)

(.46,6.0)

(.35, 2.8)

(.52,2.8)

95% Confidence Interval

Table 4. Odds Ratios of Cobalamin Deficiency for Cases to Control Subjects or "True" *Control Subjects

CD

30

30

30

n

30

30

30

30

30

30

Controls

Controls

Controls

TRUE * CONTROLS

Controls

Controls

Controls

Controls

Controls

Controls

40

Cases without Cognitive Impairment

23

Peripheral neuropathy with
Paresthesia & paresthesia only

(.68, 16.3)
3.3
10

Positive Romberg

(.36, 17.6)
2.5

6

t For this odds ratio calculation, one control with reduced cutaneous sensation is also considered a case
t For this odds ratio calculation, 28 controls with reduced vibration sense are also considered cases

(.63,8.7)

Paresthesias only

2.3

22

Reduced cutaneous sensation*

(.49, 10.2)

(.49, 10.2)

(.57, 5.3)

95% Confidence Interval

(.59,8.1)

(.51.8.6)

(.58, 6.0)

95% Confidence Interval

13

2.2

2.2

1.7

Odds
Ratio

2.2

2.1

1.9

Ratio

Odds

Absent reflexes

13

62

Reduced vibration sense*
Absent vibration sense

n

NEUROLOGICAL DEFICITS

CASES WITH SPECIFIC

17

Peripheral neuropathy with
paresthesias

& Dementia

n

CASES WITH SPECIFIC
NEUROLOGICAL DIAGNOSES

* True Controls are defined as controls with a neurological score of zero

n

TRUE* CONTROLS

True* Controls

Table 5. Odds Ratios of Cobalamin Deficiency for Subjects with Specific Neurological Diagnoses/Deficits to

.50+

S-tHcys

F-Cbl

.42*

.41*

BUN

Crt

Education

Age

-.47*
.45*

.40+

-.46*

Neuro

.29*

.32*

Age

t-Hcys

S-tHcys

.32*

Neuro

.44^

S-MMA

.39*

.43*

-.40*

-.37*

S-tHcys

S-Cbl

Variables*

CONTROLS

MMSE

Education^

BUN

Age

Neuroscore

.39*

-.40*

S-Cbl

F-Cbl

S-MMA

Variables^

CASES

.35*

Reflexia^

.33*

Vibration^

.42*

Vibration^

.28*

Romberg^

.40+

MMSE^

.34+

MMSE^

.28+

'

CD
CO

Trails B

-.40+

Trails B

.33+
.28+

Reflexia®

Trails B

.28*

.37+

BUN

.34*

.33*

Crt

.32+

Neuro

-.30+

.32+

Trails B

.37

-.32*

Education^

foods and supplements.
§ Spearman correlation coefficients were calculated.

t S-Cbi = serum cobaiamin, S-MMA = serum methylmaionic acid, S-tHcys = serum totai homocysteine,
Neuro = neurologicai score, MMSE = Mini Mental State Examination, Traiis B= trails B test score,
BUN = blood urea nitrogen, Crt = creatinine. Hot = hematocrit, Hgb = hemoglobin, F-Cbl = free Cbl from fortified

* Correlation is significant at .05 ievei (2-taiied)
t Correlation is significant at .01 ievei (2-taiied)

MMSE§

.37+

Vibration^

.31*

.34+

-.26*

.49+

s-MMA

.43+

Age

Neuro

-.42+

.49+

tHcys

F-Cbl

.28*

S-MMA

S-Cbl

Variables^

CASES AND
CONTROLS

Tables 6.(Continued)
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APPENDIX 1:

SAMPLE SIZE CALCULATIONS

96

97

Unmatched Case-Control study
Comparison of III and not III
Sample sizes for 18% Exposure in not ill group
Not ill
Conf. Power

:ill

Exposure

Odds

Sample Size

in ill

Ratio

not ill

44.87%

5.0

39

39

79

ill

Total

95%

80%

95%

80%

42.28%

4.5

45

45

90

95%

80%

39.44%

4.0

54

54

108

1:1

95%

80%

36.30%

3.5

67

67

134

95%

80%

32.81%

3.0

89

89

178

95%

80%

28.93%

2.5

131

131

262

95%

80%

24.56%

2.0

236

236 472

95%

80%

19.63%

1.5

728

728 1456

APPENDIX 2:

CONSENT FORMS FOR CONTROLS AND CASES
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• U7V/
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Jmda University
Loma Linda, California 92350
(909) 824-4546

School of Public Health

FAX: (909) 824-4087

CONSENT FORM FOR CONTROLS
VITAMIN B12 DEFICIENCY AND NEUROLOGIC DEFICIT IN OLDER ADULTS

Dr. James Larson, Dr. Daniel Giang, and Marion Bachra, a graduate
student from Loma Linda University are conducting a study in which they are
comparing the prevalence of vitamin 812 deficiency in older adults with and
without neurological deficits. We invite you to join our study. When you agree to
join the study, you will be part of the control group, that is, you and others will
serve as a reference group who experience no neurological complaints or
symptoms. The scientific literature suggest that vitamin 812 deficiency can lead
to neurological problems. Some studies have shown that older adults' food
intake, as well as the ability to absorb vitamin 812 decrease with age. This study
is attempting to quantify the current intake levels of vitamin 812.

As a participant in this study; you are being asked to answer a food
frequency questionnaire. Some blood will be drawn to assess your vitamin 812
status. You may receive the lab results. To test your neurologicalstatus, the
doctor will test your reflexes.

The only risks of the study are those associated with the usual drawing of
blood. These risks are the following; bruising due to needle puncture, and slight
discomfort after the blood is drawn. There is no cost to you or any third party

payor for any part of the study. This study may or may not benefit you, tiut it is
hoped that the obtained information will benefit humanity by increasing the
knowledge base for future research of vitamin 812 deficiency and its
complication. Further, this study might indirectly lead to potential changes in
standard medical practice. Under current medical practice, testing your vitamin
812 level is not medically necessary, since you have no neurological
complaints.

Your participation in this study is completely voluntary. You have the freedom to
withdraw at any time without compromise of your medical care.

Page 1 of 2

^ seventh-dayadventist health sciences institution
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Page 2 of 2

The information you provide will be held in complete confidence. Your identity
will not be disclosed in any published document.
"1

have read the contents of the consent form and

have listened to the verbal explanation given by the investigator. My questions
concerning this study have been answered to my satisfaction. 1 hereby give
voluntary consent to participate in this study. Signing this consent document
does not waive my rights nor does it release the investigators, institution or
sponsors responsibilities. I may call Georgia Hodgkin, Ed.D., R.D. a faculty
member at the LLU Department of Nutrition and Dietetics at(909)-824-4593
during routine office hours if 1 have additional questions or concerns. I have
been given a copy of this consent form."

"I
have been told that if I wish to contact an impartial
third party not associated with this study regarding any complaint I may have
about the study, I may contact Jean Fahnkhanel, Patient Representative, Loma
Linda University Medical Center, Loma Linda, OA 92354, Phone (909)-824-4647
for information and assistance."

I have received a copy of California Experimental Subject's Bill of Rights and
have these rights explained to me.
a.

Signature of Subject

Date

Witness

b. Subject is unable to sign because.

Authorized signature

Relationship

Date

c. "I have reviewed the contents of the consent form with the person signing

above. I have explained the potential risks and benefits of the study."

Signature of Investigator

Phone

Date

• U/Vy
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jQnda TIniversity
School of Public Health

Loma Linda, California 92350
(909) 824-4546
LUX: (909) 824-4087

CONSENT FORM FOR CASES
VITAMIN B12 DEFICIENCY AND NEUROLOGIC DEFICIT IN OLDER ADULTS

Dr. James Larsen, Dr. Daniel Giang, and lVlarion Bachra, a Loma Linda
University graduate student, with the help of other Faculty Medical Offices'
doctors, are conducting a study. In this study they are comparing the prevalence
of vitamin B12 deficiency in older adults with and without neurological deficits.
Your doctor has ordered a vitamin B12 test for you, because you have a
neurological deficit. We therefore, invite you to join our study. The scientific
literature suggest that vitamin B12 deficiency can lead to neurological problems.
Some studies have shown that older adults'food intake, as well as the ability to
absorb vitamin B12 decrease with age. This study is also attempting to quantify
your current dietary vitamin B12 levels.

As a participant in this study, you are being asked to answer a dietary
questionnaire. As part of regular medical procedures, your blood will be drawn
to assess your vitamin B12 status. You will receive the lab results. Your doctor

has neurologically assessed you by performing some simple tests.
No discomfort or risks are anticipated. This study may or may not benefit
you, but it is hoped that the obtained information will benefit humanity by
Increasing the knowledge base for future nutritional counseling and for research
of vitamin B12 deficiency and its implications. This study might indirectly lead to
potential changes in standard medical practice.

Your participation in this study is completely voluntary. You have the
freedom to withdraw at any time without compromise of your medical care.

Page 1 of 2

a seventh-day adventist health sciences institution
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Page 2 of 2

The information you provide will be held in complete confidence. Your identity
will not be disclosed in any published document.

"I

'

have read the contents of the consent form and

have listened to the verbal explanation given by the investigator. My questions
concerning this study have been answered to my satisfaction. I hereby give
voluntary consent to participate in this study. Signing this consent document
does not waive my rights nor does it release the investigators, institution or
sponsors responsibilities. I may call Georgia Hodgkin, Ed.D., R.D. a faculty
member at the LLU Department of Nutrition and Dietetics at(909)-824-4593
during routine office hours if I have additional questions or concerns. I have
been given a copy of this consent form."

"I
have been told that if I wish to contact an impartial
third party not associated with this study regarding any complaint I may have
about the study, I may contact Jean Fahnkhanel, Patient Representative, Loma
Linda University Medical Center, Loma Linda, OA 92354, Phone (909)-824-4647
for information and assistance."

I have received a copy of California Experimental Subject's Bill of Rights and
have these rights explained to me.
a.

Signature of Subject

Date

Witness

b. Subject is unable to sign because_

Authorized signature

Relationship

Date

c. "I have reviewed the contents of the consent form with the person signing
above. I have explained the potential risks and benefits of the study."

Signature of Investigator

Phone

Date

APPENDIX 3:

DATA COLLECTION FORMS
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NEUROLOGICAL SCORING SHEET
PATIENT NAME & MEDICAL RECORD

#
PARESTHESIA

NEUROLOGIC

Yes

NO

SCORES

SCORES

SCORES

same=0

reduced=

absents4

SCORES

SCORES

3errors3

4errors4

TESTS
VIBRATION
SENSE

JOINT

2

0error=0

1error=1

2errors2

POSITION

or

SENSE

CUTANEOUS

SerrorsS

sahie=0

SENSATION

reduceds

absents4

2

PLANTAR

normal

detect.

detect,

absent

hyper-

REFLEXIA

reflex=0

hypo-

hyper-

reflexs4

reflexla

reflexia=2

reflexia

with

s2

clonuss4

PLANTAR

up=2

RESPONSE

ROMBERGISM

MAX PTS 23
TOTAL
POINTS

sideways
=0

absents

presents

0

4

downsO
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MINI MENTAL STATUS EXAM

ORIENTATION TO TIME 5PTS
MAX

ORIENTATION TO PLACE 5PTS
MAX

REGISTRATION 3 WORDS 3PTS
MAX

ATTENTION & CALC.5 PTS MAX

RECALL OF 3 WORDS 3 PTS MAX
LANGUAGE

8 PTS MAX

VISUAL CONSTRUCTION 1 PT
MAX

(MAX. PTS 30)TOTAL POINTS
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The Mini Mental State Exam(MMSE)
Maximum

Score

Score

'

^

ORIENTATION

5

()

1. What is the (year)(season)(date)(day)(month)?

5

()

2. Where are we:(state)(county)(hospital)(floor)?

3

( )

3. Name 3 objects: 1 second to say each. Then ask
the patient all 3 after you have said them.
Give 1 point for each correct. Then repeat them until
s/he learns all 3. Count trial and record
Trials
ATTENTION AND CALCULATION

5

( )

4. Serial 7s. 1 point for each correct. Stop after 5
answers.

Alternatively, spell "world" backwards, if s/he cannot
subtract.
RECALL

3

( )

5. Ask for 3 objects repeated above.
Give 1 point for each correct.
LANGUAGE

9

( )

6. Name a pencil and watch (2 points)
7. Repeat the following "No ifs, ands or buts" (1 point)
8. Follow a 3-stage command:"Take a paper in your
right hand, fold it in half and put it on the floor."
(3 points)

9. Read and obey the following: "Close your eyes"
(1 point)
10. Write a sentence. (1 point)

11. Copy design. (1 point)
Total (

)
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Trail Making Test - Part B

13

D

B

®

^in

H

©

0
(2)

© ^

(6
©
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PATIENT PROFILE SHEET

Name

LL#

Sex
Age
Marital Status

Religion

Education
Ht
Living situation

Wt

BMI

'

LAB VALUES

Serum B12
MCV_
Hot
Serum Gastrin

Serum MMA
Serum HCYS
Hab
Crt
BUN
Alb
Choi
Other

DIETARY HISTORY

FFQ B12
Vegetarian No

B12 Supplement
Yes
Type

Free B12.

MEDICAL HISTORY

Diagnosis/ICD-9 codes
Past Medical History;
Alcohol use >280 gm/week yes

'
•
no_

Gastrectomy partial
total
none_ Heal resection ves
no
date
Atrophic Gastritis(AB against parietal cell, IF, elevated yes
no_
gastrin, abnormal
Schilling test)
Hematological malignancy no
yes
type
Celiacs disease (Tropical Sprue) yes
no
Cerebral vascular accident yes
when
Multiple myeloma(B12) yes
when
no

no_

Other conditions
MEDICATIONS

Antibiotics use: currently
date last used
Type
Antisecretory, Antiulcer
Histamine H2 Antagonists Yes _No
Omeprazole (Prisosec)
Cimetidine (Tagamet)
Antacids Yes

Other.

No

Type
Corticosteroids (folate) Yes_
No
Type
Laxatives Yes^
No
^Type
Cytotoxic drugs Yes
No
^Type

^

Sedative, Sleep Aid
Chloral Hydrate
Yes ' No
Antihypertensive,Diuretic, K sparing
Spironolactone (Aldactone) Side effect: Ataxia, Confusion Yes
Bile acid Sequestrant(folate)
Colestyramine Yes
No
Dilatin (B12) yes
no
Diphenylhydantoin (B12) yes
no
CURRENT MEDS

No_
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CHECK LIST FOR VITAMIN B12 STUDY

PATIENT NAME

LL MEDICAL RECORDS#_
FIRST VISIT

PATIENT AND PHYSICIAN BOTH SIGNED CONSENT FORM

YES_

MINI MENTAL STATUS EXAMINATION

SCORE.

TRAILS B COGNITIVE EXAM

TIME _

ERRORS OF OMISSION
PARESTHESIA

ERRORS OF COMMISSION

YES^

NO.

NEUROLOGICAL TEST

SCORE.

PATIENT FILLED OUT FOOD QUESTIONNAIRE

YES

ORDERED SERUM B12 ON SPECIAL LAB SLIP

YES

SEND PATIENT WITH SPECIAL LAB SLIP TO THE FMO

NO.

YES

SEND CONSENT FORM, NEUROLOGICAL TEST, FOOD QUESTIONNAIRE TO
MARION BACHRA

LLU/SPHBOX260

YES

SECOND VISIT

SERUM B12

RESULT(PG/ML)_

ORDERED SERUM MMA/HCYS ON A REGULAR LAB SLIP

IF SERUM B12 IS <350PG/ML(CASES ONLY)
SERUM MMA
SERUM HCYS
SEND COPY OF CHECK LIST TO MARION BACHRA

YES
RESULT(NMOUL).
RESULT(UMOL/L_

APPENDIX 4:

DIETARY QUESTIONNAIRE
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LOMA LINDA UNIVERSITY
DEPARTMENT OF NUTRITION

DIETARY QUESTIONNAIRE

(Vitamin B|2 Study)
Chart #

Date

Name

Received by

Dear Participant,

Thank you very much for your willingness to participate in this study, in order to
get an idea of your dietary habits, you wiii be filiing out this questionnaire. First, we will ask
you about your vitamin suppiement usage, then we wiii ask you about your food
consumption.

If you take any vitamin supplements, oraily or by injection, please indicate in the
table below, the brand name (oral supplements only), how often you take them, and the
amount of vitamin B,2 in micrograms.
TYPES OF

SUPPLEMENTS

AMOUNT OF

BRAND NAME

HOW OFTEN

VITAMIN B,2

MULTIVITAMIN
Micrograms
VITAMIN B COMPLEX

OR VITAMIN B,2 pills

Micrograms

SUBLINGUALB,2
CAPSULES

Micrograms

VITAMIN B,2
INJECTIONS

Micrograms

If you do not know the amount of vitamin 8,2 you take, couid you please check at home
the label on your vitamin bottie. Vitamin 8,2 may be listed as cvanocobalamin on the label.
Please write down your phone number. Area code
telephone number
When is the best time to cali you?

Piease check off(/), mornings □ afternoons □ eveningsD
Please turn to the back of this page
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EXAMPLE OF HOW TO FILL OUT THE QUESTIONNAIRE
FOR EXAMPLE,if you drink two cups of milk once a day, never eat ice cream or frozen
yogurt, eat one cup of flavored yogurt about once a week, and eat about three cups of
custard three times a month, you would write that down as shown in the example below.
THIS IS AN EXAMPL ONLY!
FOOD/NAME/

SERVING

RARELY/

DESCRIPTION

SIZE

NONE

Milk ofany type

1 cup

Ice cream,frozen yogurt

1 cup

Plain or flavored yogiut

1 cup

Pudding or custard

1 cup

DAY

WEEK

MONTH

V

PLEASE FILL OUT THE REST OF THIS QUESTIONNAIRE
For each food listed in the questionnaire, indicate the number of times, on average, you
have consumed these food during the past year. Please fill it out as accurately as you can.

1. How many times do you eat the following EGGS AND DAIRY PRODUCTS, plain or as
part of an entree. Please write down the number of times, if any, you eat these items on
FOOD/NAME/

SERVING

RARELY/

DESCRIPTION

SIZE

NONE

Milk of any type

1 cup

Ice cream,frozen yogurt

1 cup

Plain or flavored yogurt

1 cup

Pudding or custard

1 cup

Cottage cheese

'A cup

Hard cheese

1 ounce

Cream cheese

1 ounce

Sour cream

2 tablespoons

Whole egg

1 each

Egg substitute

1/4 cup

DAY

WEEK

MONTH
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2. How many times do you eat the following MEAT,POULTRY, AND FISH products.
FOOD/NAME/

SERVING

RARELY/

DESCRIPTION

SIZE

NONE

Beef,lamb, or pork

Bounces

Chicken, turkey, or duck

3 ounces

Sausages or hotdogs

Teach

Limcheon meat

1 slice

Bacon

2 strips

Organ meat

3 oimces

Shellfish

3 ounces

Fish

3 ounces

DAY

WEEK

MONTH

3. You might eat MEAT SUBSTITUTES or MEAT ANALOGUES, if you don't, please

check off(/)this box □. If you do, please write down, as shown in the examples below.
FOOD/NAME/

SERVING

DESCRIPTION

SIZE

DAY

WEEK

iFor^aiapk:

3

IftforthiiKibw,PrwtswMft. Rock
j

Wor{lil>i4fro^f
j
^

'

j

1slice.

1

Please turn to the back of this page

MONTH
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4. How many times do you eat the folldvying CEREAL OR BREAD PRODUC
FOOD/ NAME/

SERVING

RARELY/

DESCRIPTION

SIZE

NONE

Pancakes or waffles

1 each

Muffins

1 each

French toast

leach

WJite

iha

WEEK

DAY

fypes efhotor ool4 ceroal($)

S.
MONTH

yoh ose

1 cup

3

Fost, Go!<b\Cnsi> : 1 cup

2.

Q/
"""

^ :.—-—

—

■•"1 •

■

'

5. You might drink LIQUID FOOD SUPPLEMENTS, like Sustacal or Ensure.

If you don't, please check off (/) this box □. 1 you do, please write down as shown in
the example below the brand names of the supplements you use.
FOOD/NAME/

SERVING

DESCRIPTION

SIZE

feriSvitc..Ltahb

icon

DAY

WEEK

MONTH

!

J

Thank you very much for taking the time to fill out this questionnaire!

LLU Departement of Nutrition, February 1997. Developed by Marion Bachra and Joan Sabat6
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ADDITIONAL STUDY RESULTS

115

17.9(4.5)

422(214)
21.5 (9.6)

1.2 (.4)

14.6(1.4)
5.4(2.1)

462(232)

BUN*(mg/dl) 18.6(6.0)

1.0(0.3)

91.4(3.9)

40.3(3.9)

13.8(1.4)

3.9 (2.0)

Cbl*(pg/mlf

Crt* (mg/dl)

MCV* (fl)

Hct*(%)

Hgb* (g/dl)

Diet* Cbl

(meg)

13.4(2.1)

13.9(2.6)

13.7(2.4)

Educ.(yrs)

15.2(1.4)
4.2(1.1)

15.0(1.2)
3.3(2.3)

14.9(1.1)

5.2(2.9)

4.3(2.5)

12.3(1.7)

4.7 (2.2)

13.4(1.4) .

39.6(4.1)

36.5(4.8)
43.4(3.5)

43.5 (3.4)

43.5(3.7)

42.8 (4.1)

88(3.4)
92.6(6.2)

92.1 (4.7)

90.8(4.5)

90.8 (4.0)

1.0 (.20)

18.0(6.4)

533(196)

12(2.0)

11/5

87.6 (2.7)

1.0(.16)

.97(.09)

.98 (.19)

1.0 (.2)

415(221)
18.1 (8.9)

444(269)

12(3.3)

12.3(2.6)

17.3(2.5)

312(139)

15(2.8)

3/1

3/1

79(5)

Mean (SD)*

Mean(SD)^
81(4)

n=16

peripheral
neuropathy

Dementia
w/and w/o

n=4

Cognitive
Impairment

Mild

82(9.3)

Mean (SD)^

n=4

Gait
imbalance

19.3(4.8)

417(221)

5/12

7/6

30/30

Sex F/M

4/2

77(5)

76(8)

82(12)

79(6)

n=6

Age (yr)

paresthesia
n=17

paresthesia
n=13

Only

Mean (SD)*

with

without

Paresthesia

Mean(SD)^

Peripheral
neuropathy

Peripheral
neuropathy

Mean (SD)^ Mean (SD)*

n=60

Controi

Variable

Diagnosis

APPENDIX 1. Characteristics of Controls and Cases Categorized by Clinical Diagnosis

O)

1 (1.4)

128(60)

29(1)

9(4.7)

150(49)

29(1)

4.5 (7.7)

7(3.9)

141 (52)

29(1)

5.3(8.0)

5.5 (8..8)

Mean(SD)*

n=17

2(.82)

115(46)

29(1)

9.3(12.4)

5.6(10.4)

Mean(SD)*

n=6

Paresthesia

5(1.0)

196(43)

29(1)

1.5(3.0)

1.9(2.9)

Mean (SD)^

n=4

4(1.6)

175(88)

25(1)

3(3)

220(83)

14(7)

4.2(7.1)

3.7(4.4)

2.6 (2.7)

3.0 (3.5)

Mean (SD)^

n=16

peripheral
neuropathy

Dementia
w/andw/o

Mean(SD)*

n=4

Mild

Cognitive
Impairment

Gait
Imbalance

isD = standard deviation

supplements only, MSSE = Mini Mental State Examination.
tTo convert Cbl values to pmol/L, divide by 1.355.

*Cbl = cobalamin, BUN - blood urea nitrogen, Crt = creatinlne, MCV = mean cell volume, Hct = hematocrit, Hgb = hemoglobin
Diet Cbl = dietary Cbl intake only. Free Cbl = free Cbl obtained from fortified food and supplements, SuppI Cbl = free Cbl obtained from

Neuro Score

score (sec.)

Trails B

score

MMSE*

(meg)

Suppi* Cbl

6.7(8.1)

5.9(8.1)

7.7(8.1)

Free* Cbl

(meg)

Mean (SD)*

paresthesia

paresthesia
n=13

with

without

Mean (SDy^

Peripheral
neuropathy

Peripheral
neuropathy

n=60

Control

Variable

Diagnosis

APPENDIX 1 (continued)

13(21.7) 3(23)
2(15.4)

2 (5.4)

5(8.3)

4(6.7)

> 2 SD MMA*

>2SD tHcys^

1 (5.9)

13(21.7) 3(23)

1 (1.7)

Cbl deficiency*

Possible Cbl

11 (64.7)

1 (16.7)

2(33)

3(50)

1 (16.7)

1(16.7)

1 (16.7)

2(33)

2(33)

No.(%)

n=6

Only

Paresthesia

0(0)

1 (25)

3(75)

0(0)

1 (25)

0(0)

0(0)

1 (25)

No.(%)

n=4

Gait
Imbalance

0(0)

1 (25)

3(75)

0(0)

1 (25)

0(0)

0(0)

1(25)

No.(%)

n=4

Cognitive
impairment

Mild

1 (6.3)

3(18.8)

12(75)

1 (6.3)

3(18.8)

0(0)

1 (6.3)

3(18.8)

No.(%)

n=16

peripheral
neuropathy

Dementia
w/ and w/o

§ Possible Cbl deficiency is defined as a tHcys level >13.9 umol/L with a MMA level <272 nmol/L and a serum folate level of < 5ng/L

level >13.9 umol/L and a serum folate ^ 5 ng/ml.

t Cobalamin (Cbl) deficiency is defined as a MMA level >271 nmol/L or a MMA level >271 nmol/L & a tHcys level > 13.9 umol/L or a tHcys

t Normal range for serum total homocystelne (tHcys) is ± 2 SD or 5.1-13.9 umol/L

0(0)

47(78.3)

None elevated

Deficiency^

5(29.4)

10(77)

1 (1.7)

tHcys only
1 (5.9)

0(0)

9(15)

4(23.5)

1 (5.9)

2 (11.8)

5 (29.4)

No. (%)

n=17

MMA only

tHcys elevated
1 (7.7)

No. (%)

Both MMA &

n=13

No. (%)

paresthesia

paresthesia

n=60

with

without

Criteria

Peripheral
neuropathy

Peripheral
neuropathy

Diagnostic

Controls

Controls and Cases categorized by Clinical Diagnosis

APPENDIX 2. Frequencies of Elevated Serum Methylmalonic acid and Serum Total Homocystelne among

CO

No. (%)

No. (%)

No. (%)

4(100)

0(0)

3(75)

1 (25)

0(0)

6(100)

17(100)

0(0)

0(0)

Present

1 or more errors

0 errors

Joint position
8(61.5)
5(38.5)

60(100)

0(0)

0(0)

1(25)

3(17.6)

8(61.5)

0(0)

Absent

6(100)
0(0)

13(76.4)
4(23.6)

13(81.1)
2(12.6)

4(100)
0(0)

4(100)
0(100)

1(6.3)

10(62.5)
4(10)

2(50)

3(50)

11 (64.7)

4(30.8)

28(46.7)

Reduced

0(0)

5(31.2)
0(0)

1 (25)

3(50)

3(17.7)

1(7.7)

32(53)

Normal

1 (6.3)

15(93.7)

No. (%)

No. (%)

No.(%)

0(0)

N=16

n=4

13(100)

Vibration Sense

Dementia
w/ and w/o

Cognitive
impairment peripheral
neuropathy

Mild

n=4

Gait
Imbalance

60(100)

No. (%)

n=6

Only

Paresthesia

Absent

Paresthesias

n=17

paresthesia

paresthesia
n=13

n=60

with

w/o

Neurological
Signs

Peripheral
neuropathy

Peripheral
neuropathy

Controls

Diagnosis

Clinical Diagnosis

APPENDIX 3. Frequencies of Neurological Signs and Symptoms among Controls and Cases Categorized by

<o

No. (%)

0(0)

0(0)

Absent

5(29.4)

7(53.8)

0(0)

Absent

15(88.2)
2(11.8)

6(46.2)
7(53.8)

60(100)

0(0)

Absent

Present

Rhomberg

0(0)

0(0)

0(0)

Hyper

10(58.8)

8(13.3)

Hypo

5(38.5)

52(86.7)
2(11.8)

0(0)

11 (64.7)

6(35.3)

No. (%)

n=17

Normal

1 (7.)

3(23.1)

1 (1.7)

Reduced

Piateiiar Reflex

10(76.9)

59(98.3)

Normal

Cutaneous Sense

n=13

0(0)

6(100)

0(0)

1 (16.7)

1 (16.7)

4(66.6)

0(0)

2(33.3)

4(66.7)

No. (%)

n=6

paresthesia

paresthesia

No. (%)

with

without

n=60

neuropathy

Neurologicat
Signs

Paresthesia

Only

Peripheral

Peripheral
neuropathy

Controls

Diagnosis

APPENDIX 3(continued)
Gait

1 (25)

3(75)

0(0)

0(0)

2(50)

2(50)

0(0)

1(25)

3(75)

No.(%)

n=4

Imbalance

0(0)

4(100)

0(0)

0(0)

3(0)

1 (25)

0(0)

1 (25)

3(75)

No. (%)

n=4

Cognitive
Impairment

Mild

0(0)

16(100)

1 (6.2)

0(0)

5(31.3)

10(62.5)

0(0)

3(18.7)

13(81.3)

No.(%)

n=16

peripheral
neuropathy

w/ and w/o

Dementia

ro
o
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